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Potent vaccine formulations ideally include adjuvants to activate innate immune 
responses and enhance antigen-specific adaptive immunity. The synthetic glycolipid alpha-
Galactosylceramide (α-GalCer) effectively activates the innate immune mediating NKT cells 
to produce cytokines and activate downstream immune cells, resulting in development of 
humoral and cell mediated immune responses to co-administered antigens. While a single 
intravenous immunization of α-GalCer strongly activates NKT cells, multiple doses by this 
route are well documented to induce anergy in NKT cells. Anergy is defined as the 
deficiency in NKT proliferation and cytokine production, including IL-4 and IFNγ. However, 
our studies have shown that two doses of α-GalCer administered intranasally by the 
intranasal route leads to reactivation of NKT cells and improved adaptive immune responses 
after each subsequent dose. I therefore investigated the role of multiple routes of 
immunization in activation of NKT cells, i.e. anergy versus repeated activation. Specifically, I 
hypothesized that the differential capacity of NKT cells to produce IFNγ, as a result of route 
of immunization with α-GalCer, influences the induction of adaptive immune responses to 
co-administered antigen. Our experimental design utilizes the observation that intranasal 
immunization primarily induces immune responses in the lungs while intravenous 
immunization induces responses in the liver. 
Using intracellular cytokine staining for IFNγ production and Elispot analyses for 
determining NKT and T cell activation, respectively, it was determined that administering two 
consecutive intravenous doses resulted in anergy to NKT cells (no IFNγ production) in the 
liver and lack of adaptive immunity while second immunization by the intranasal route 
overcame anergy in the lung. The outcome in the other tissues analyzed was mixed and 
could be the result of tissue microenvironment among others possible reasons. When 
intranasal dosing preceded systemic, NKT cells were reactivated to produce IFNγ and 
induced positive adaptive immune responses in the responding lung tissue. These results 
indicate that the mechanism by which mucosal and systemic immunization routes activate 
NKT cells may differ in that there is a differential tissue-specific effect induced by each route. 
Future studies are necessary to determine the reason for these tissue-specific effects and 
how they relate to NKT cell activation. 
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CHAPTER 1: INTRODUCTION AND BACKGROUND 
1.1 MUCOSA AND ADJUVANTS 
1.1.1 Mucosal Immunity 
 
The mucosal membranes make up an area of several hundred square meters in 
adult humans (1). A substantial number of infectious agents, estimated around 70%, enter 
the body via mucosal surfaces including the digestive, respiratory, and genitourinary tracts 
(2, 3). Unlike systemic immunization, mucosal vaccination has the ability to activate multiple 
arms of the immune system in order to combat pathogens that cannot be contained by 
antibody responses alone; they may be ideal for inducing immune responses to protect 
against pathogens entering via mucosal portals. Mucosal vaccines offer additional 
advantages such as avoiding the use of needles that carry the risk of possible spread of 
blood-borne pathogens, and also ease of use facilitating both better compliance and 
administration by non-medically trained personnel (4). The mucosal associated lymphoid 
tissues function to protect the mucosa from invasion by microbial pathogens, prevent the 
uptake of harmless antigens such as those from commensal bacteria and non-degraded 
food proteins, and to induce tolerance against commensal bacteria and soluble antigen (1). 
Due to constant assault by environmental antigens, mucosal tissues exert tolerance as the 
natural response to most invading foreign pathogens (4). Tolerance at mucosal tissues 
prevents the generation of inflammatory responses to harmless antigens like those found in 
the air or in food. Tolerance is mediated by the mucosal immune system that is made up of 
lymphoid and non-lymphoid cells, and effector mechanisms mediated by antibodies, T cells, 
and cytokines (2). In response to infection, the mucosal immune system activates innate 
and adaptive immune responses to provide protection. Organized lymphoid tissues, 
including the tonsils and adenoids, and Peyer’s patches of the intestinal tract, are found in 
areas where pathogens are most likely to enter the body, and they house the machinery to 
allow B cell isotype switching from IgM to IgA, the major class of immunoglobulin in mucosal 
secretions (2, 5). . The presence of these organized lymphoid tissues allows for the 
differentiation of follicle-associated epithelium (FAE) containing microfold “M” cells that 
deliver antigen samples to local underlying dendritic cells (DCs) and lymphocytes by 
transcytosis (3, 5, 6). This creates a high density of cells that can phagocytize pathogens 
directly at their port of entry to ultimately limit systemic infection. In tissues lacking M cells, 
such as the genital mucosa, DCs migrate directly to the epithelial spaces to sample foreign 
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antigen where they can act locally or migrate through the lymphatic system to draining 
lymph nodes and even other organized lymphoid tissues such as distant lymph nodes and 
the spleen (7-9). The primary type I mucosae effector sites, the lung and gut, are protected 
by immunoglobulin IgA and utilize both mucosal DCs and M cells to pick up and present 
antigen within mucosal-associated lymphoid tissue (MALT) (8, 10, 11). In contrast, the 
tissues of the type II mucosae, the mouth, esophagus, and cornea, are primarily protected 
by IgG and lack MALT. They must rely on migration of activated antigen-presenting DCs to 
activate naïve lymphocytes in the peripheral mucosa-draining lymph nodes (12). 
After antigen presentation, innate immunity goes on to activate adaptive immune 
responses. Innate immunity is the body’s first line of defense against foreign pathogens. 
Made up of anatomical barriers, the complement system, and inflammatory cells, the innate 
immune system is designed to act quickly and indiscriminately to neutralize foreign invaders. 
Innate immunity relies on non-specific surface pattern recognition receptors (PRRs) on 
epithelial cells, such as toll-like receptors (TLRs) and NOD-like receptors (NLRs), retinoic 
acid (RA)-inducible gene I-like helicases, and C-type lectins (13, 14). The PRRs recognize 
pathogen-associated molecular patterns (PAMPs), which represent conserved 
characteristics of bacteria and viruses such as peptidoglycan or double-stranded RNA, and 
thus mount an immune response (2, 15, 16). Such PAMPs have been identified in many of 
the mucosal surfaces, for example the NOD1 receptor in the lung and its role in asthma (17), 
TLR7 in the human intestine, and TLR4 in the genital mucosa (1). It is the innate system 
which is responsible for activating APCs such as DCs by sending out chemokines and 
cytokines in response to PRRs interacting with PAMPs; the APCs then go on to link the two 
systems and present antigen to the adaptive effector cells. The B and T cell effectors of 
adaptive immunity express antigen-specific receptors which, when activated, trigger 
expansion and memory to repeated antigen exposure. Many studies have described the 
existence of the common mucosal immune system (CMIS), in which antigen-specific 
lymphocytes can home not only to the site of pathogen presentation but also to other distant 
mucosal effector sites (13, 18). This effect depends on mucosal compartmentalization, “the 
process of antigen uptake, migration, and processing by local APCs and magnitude and 
phenotype of T cells or predominant antibody isotype(s) induced in relationship to the route 
of immunization and mucosal site(s) analyzed” (13). For example, IgA secreting B cells in 
the mucosa express CCR10, the receptor for CCL28 expressed by epithelial cells in various 
mucosal tissues including intestines and the respiratory tract (5, 19). Thus, the responding 
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cells can migrate to CCL28-expressing tissues, explaining the far reaching responses of the 
common mucosal immune system. In general, these compartmentalized immune responses 
include innate, serum IgG and serum IgA, and cytotoxic T lymphocyte (CTL) responses in 
the local tissue that confer protection against mucosal pathogens. Mucosal vaccines 
approved for use in humans to date include those targeting poliovirus (20), influenza virus 
(21), Salmonella typhi (22), and V. cholera (22, 23). While systemic vaccine delivery 
involves immunizing with a known amount of antigen and measuring responses in the 
blood,administering mucosal vaccines is complicated by the fact that antigen uptake cannot 
be measured, and mucosal responses are more difficult to detect. Thus, improvement in the 
breadth and caliber of mucosal vaccines is necessary.  
1.1.2 Overcoming the mucosal barrier 
 
 Within the mucosal tissues, mucous acts as a barrier to pathogen entry and 
movement, thus doubling as a potential barrier to vaccine delivery as well. Various methods 
are being developed to overcome these disadvantages, including engineering vaccine 
vehicles to take advantage of surface charges on mucous to better adhere to or penetrate it 
(2, 24, 25). Another strategy, developed by Ralph Steinman’s group, focuses on targeting 
vaccines directly to the dendritic cells using DC-specific receptors expressed on the surface 
(2, 26-28). Various cell types can be targeted using natural ligands or even antibodies to 
their receptors (29). Timing of antigen and adjuvant delivery is also important. While co-
delivery of adjuvant with antigen has been shown to enhance CD8+ T cells responses (2, 
29-31), delivering these components separately leads to enhanced antibody titers (2, 32). 
Interestingly, it has also been shown that co-localization of antigen and TLR ligand adjuvant 
within the same phagosome is necessary to induce DC maturation and thus antigen 
presentation (2, 33). A study using the vaginal route to deliver HIV antigen revealed that 
repeated immunization without the use of adjuvant induced antibody responses (2, 34). 
This, however, is in contrast to the general perception that in the absence of an adjuvant, a 
state of tolerance is induced rather that immunity. Tolerance can be induced by constant 
exposure to low doses of antigen (T regulatory cells) or a sudden exposure to high levels of 
antigen (via mechanisms such as anergy and deletion), necessitating in depth kinetics 
studies for mucosal adjuvants. The ideal mucosal vaccine should encompass several 
characteristics including the ability to protect antigen from degradation, to direct antigen to 
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the appropriate cells to maximize uptake by APCs, and to preferentially assist the uptake of 
antigen and adjuvant by the same cells that are augmenting immune responses (1). 
1.1.3 Mucosal vaccination strategies 
 
Many delivery strategies for mucosal vaccines have been studied to date. Live-
attenuated viruses have been used as vaccines against influenza and rotavirus. These 
types of vaccines are composed of live bacteria or viruses that have been weakened, or 
attenuated, with respect to infectivity, but retain the immunogenicity of the parent strain.  
Attenuation can be performed by multiple passages through host cultures or even by 
selected gene deletion (2). Attenuation can be a challenge as can be optimizing the stability 
of these vaccines (4). Subunit vaccines are non-living whole-cell vaccines or pathogen-
specific proteins. Their utility is limited by the need to protect the protein from degradation in 
the mucosa as well as requiring the use of adjuvant, for which there are few approved for 
use in humans (2). Virus-like particles (VLPs) are composed of virus-derived immunogens 
that assemble into three-dimensional structures similar to the capsids of the native virus. 
They self-assemble after being recombinantly expressed in yeast, insect, or even 
mammalian cells. Examples include the Hepatitis B and Human papillomavirus vaccines (2, 
35). Unfortunately, there are several disadvantage to using VLPs such as the need for large 
scale production, purification from the expression system, and the requirement for use of 
adjuvants (2). Nanoparticle carriers are engineered to overcome the limitations presented by 
the mucosal barriers. They can be made of both organic and inorganic materials and can 
either encase the antigen or have it adsorbed to the surface (1, 36). They are ideal for 
delivering biologics such as peptides and nucleic acids, and can help with proper orientation 
of antigen and adjuvants (2, 37). Interestingly, a nanoparticle formulated α-GalCer was able 
to avoid anergy induction by targeting the appropriate APC (38). However, it is interesting to 
note that studies conflict on whether nanoparticles increase serum IgG or it remains 
unchanged (1). There are also few studies that were able to show an increase in mucosal 
IgA in response to nanoparticle formulations used for vaccination as compared to antigen 
alone (1, 39). All the same, delivery of antigen via particle theoretically leads to better 
recognition and stronger immune responses than with soluble antigens, which may require 
the help of adhesion augmenting substances such as chitosan to attach to the mucosal 
membrane (4, 40). Chitosan is thought to interact with protein kinase C to open tight 
junctions between cells and allow for better drug transport (1, 41). Chitosan has also been 
5 
 
shown to increase the adjuvanticity of cholera toxin (CT) subunit B in mice (1, 42). 
Liposomes have been shown to increase absorption of antigen in the nasal cavity (1, 43). 
While liposomes can contain many copies of antigen within and protect the antigen from 
degradation, lipid-based delivery systems are also costly and formulations may be unstable 
when stored. Examples of liposomal formulations include immune stimulating complexes 
(ISCOMs), virosomes, and proteosomes, among others (1). Virosomes and proteosomes 
have shown promising results in clinical studies (44, 45). 
1.1.4 Mucosal routes of immunization 
 
Aside from differences in formulation, several studies in the literature have 
investigated the efficacy of using various routes for vaccine delivery. It is believed that 
protective immunity against mucosal pathogens can be effective if immune responses can 
be tailored to operate at the anatomic location of invasion. The strongest responses occur 
near the site of vaccination, where cells activated by vaccines, infection, or inflammation can 
upregulate the expression of addressins on epithelial cells and homing molecules on T cells 
(5, 46, 47). Oral vaccination is ideal for simplicity’s sake. Oral vaccines target antigen to the 
gut associated lymphoid tissue (GALT), where specialized cells known as microfold cells, or 
M cells, are able to transport a broad range of materials by transcytosis (1, 48). It is well 
known that oral immunization is able to induce humoral and cellular responses both at the 
GALT and also in other mucosal compartments (1, 49). However, the GALT also plays a 
significant role in inducing tolerance to antigens presented via the oral route. Thus, oral 
immunization requires the use of higher doses of antigen as well as carriers or adjuvants, 
driving up the cost. One alternative is the use of transgenic plants as production centers and 
vehicles for mucosal vaccines, thus providing a cheaper format for production resulting in an 
edible vaccine which can protect antigen from degradation (1, 50, 51). Other examples of 
mucosal vaccination routes include the sublingual route, which enables antigen entry 
directly into the bloodstream to avoid degradation or tolerance induction (1). This route is 
currently only used in humans for allergy therapy, but studies in mice have shown that this 
route allows for broadly reaching mucosal and systemic immune responses, including 
antigen-specific T cells in the cervical lymph nodes and antibodies to VLP in the serum and 
genital tissues that provide protection against genital challenge with the specific pathogen 
(1, 52-54). One thing to keep in mind is that mice have keratinized sublingual tissues while 
humans do not, and this must be taken into consideration as it may play a role in differential 
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uptake of antigen (1). Vaginal delivery is an important potential vaccination strategy as it 
allows for strong immune responses to be induced at the site of vaccination, and because 
many STDs are transmitted via this route, it is necessary for the protective immune 
responses to be active at this site. In this tissue mainly, but also at other mucosal surfaces, 
degradation-resistant dimeric serum IgA is made, which might be important in blocking 
infection at this site (1, 55, 56). It is noted that sIgA acts to trap antigen in the mucous to 
block pathogens from directly contacting the mucosal surfaces (5, 57). It may also sterically 
hinder pathogens from attaching to cells (5, 58). Vaccination strategies at this site not only 
aim to induce immune responses, but may actually aim to block antigen entry at the site. For 
example, estradiol has been shown to both prevent CD8+ T cell priming as well as antigen 
loading onto vaginal APCs (1, 59, 60). However, this route of vaccination is not only 
impractical, but is also prone to be influenced by hormonal changes during female menstrual 
cycles, which affect the levels of IgG and IgA secretions (1, 5, 56, 61). Intranasal delivery is 
also of interest given the ease of application and the requirement of less antigen and 
adjuvant than the oral route. The intranasal surfaces are small and lack enzymes that can 
cause breakdown of antigens allowing for lower doses to be effective, thus making the 
intranasal route ideal for mucosal vaccination. Intranasal administration has been shown to 
induce mucosal IgA in multiple tissues including salivary glands, the respiratory tract, genital 
tract, and the intestines (56, 62, 63), as well as CTLs in the female genital tract (64). In 
humans, studies showed broadly disseminated immunity at multiple systemic and mucosal 
tissues after intranasal vaccination against diphtheria, tetanus, and influenza (1, 65, 66). 
Similar to the oral route, the intranasal route also takes advantage of the transcytosing 
properties of M cells in the nasal associated lymphoid tissue (NALT). The NALT in mice is a 
smooth dome containing M cells, while human NALT has crypts containing M cells which 
can create germinal centers similar to those in the GALT, a phenomenon not seen in mice 
(1, 67, 68). As evidence of its widespread reach, intranasal immunization primarily induces 
immune responses in the lung and respiratory tracts, but can also reach sites such as the 
gastric and genital mucosa (4). It has also been shown to induce antibody responses in the 
genital tract (69). In fact, some intranasal vaccines, such as FluMistTM (MedImmune 
Vaccines Inc.), are approved by the FDA for use in patients. The ideal intranasal 
immunization will protect the antigen from degradation long enough to allow its interaction 
with the proper cells, stimulate both innate and adaptive humoral and cell-mediated 
responses, and, if necessary, include adjuvants that protect the natural function of the nose 
and avoid reactogenicity and toxicity (1). Optimal protection against pathogenic invasion will 
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likely require involvement of both systemic and mucosal immune responses, and thus may 
require a combination of systemic and mucosal vaccinations delivered as prime-boost 
combinations. It has been shown that mucosal immunization can prime lymphocytes by 
inducing expression of homing receptors targeting both systemic and mucosal tissues (5, 
19). However, “parenteral priming might not prime the immune system for subsequent 
mucosal vaccination” (70). 
 
1.2 ADJUVANTS 
1.2.1 What is an adjuvant? 
 
An adjuvant is defined as a substance that can enhance, prolong, or accelerate 
immune responses to co-administered antigen. Adjuvants are important to include in 
mucosal vaccines as they improve immunogenicity and help overcome the natural barriers 
against immune response presented by the mucosa. Adjuvants act by harnessing innate 
immunity to induce effector rather than regulatory T cell responses. Responses must be 
potent, but not so potent as to become toxic. Currently, the only adjuvants approved for use 
in humans include aluminum salts (alum), such as aluminum phosphate and aluminum 
hydroxide, and certain squalene oil emulsions (namely AS03) used in the H5N1 influenza 
vaccine (71-73). Both of these adjuvants are aimed at enhancing systemic immunity and are 
ineffective at producing protective responses at mucosal sites. In addition, a mixture of 
aluminum hydroxide and monophospholipid (MPL) A, an LPS analogue, make up AS04 
adjuvant used in hepatitis B virus and human papilloma virus vaccines (71, 74). Alum 
adjuvant works by inducing an influx of innate immune cells, including neutrophils, DCs, and 
NK cells, at the site of injection (75-78). It is also thought to act as an antigen depot, slowly 
releasing antigen to the environment (71). Alum adjuvant induces release of endogenous 
danger signals, including release of uric acid which degrades RNA and DNA in addition to 
releasing host dsDNA which is recognized by TLR9 (76, 79). With respect to other agents 
with known adjuvant functions, the underlying mechanisms of action are not well 
understood, adding another road block to their use in the development of vaccine 
formulations. Additionally, while mucosal immunization can induce both systemic and 
mucosal immunity, most antigens are poor immunogens and can even induce tolerance, 
thus highlighting the importance of adjuvant discovery (80). Adjuvants can be classified into 
two subgroups, those that interact with innate immune players to enhance adaptive 
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responses, and those that facilitate delivery of antigen in order to harness the CMIS. 
Adjuvants are thought to primarily function by creating an inflammatory environment that 
recruits important innate immune players, such as those with antigen presenting functions, 
to the site of interest (2). They can further act by causing the release of cytokines and 
activating APCs to allow for improved antigen presentation. Adjuvants such as cholera 
enterotoxin (CT) are known to confer protective immunity but have not been connected to an 
innate immune mediator (2). 
1.2.2 Danger model 
 
In the classical immunological model of self/non-self-discrimination, in which 
encountering foreign antigen initiates an immune response, the need for adjuvants in 
vaccine formulations could not be explained. In 1994, in partnership with Fuchs, Matzinger 
published a paper detailing their Danger model of immune activation (81). This theory claims 
that an immune response is not induced by foreign antigen itself, but by alarm signals sent 
out by the body tissues after they incur damage caused by the carrier of the antigen, for 
example, cells which are damaged or send out distress signals, or cells that die by necrosis 
or abnormal induced cell death (82). These distress signals activate the APCs (and thus the 
immune system), not the presence of foreign antigen, which may or may not be harmful 
(83). Similarly, abnormal reactions of the body that cause injury to cells can activate the 
immune system, even though these are self-cells. Examples of endogenous danger signals, 
or adjuvants, include IFNα, heat shock proteins, necrotic cell death, activation of NF-kB, and 
blood clotting factors (82). Heat shock proteins, or HSPs, are evolutionarily conserved 
proteins that play a role in protein folding and transport, and are upregulated when cells 
experience stress, for example at high temperatures. They are capable of presenting 
antigens to APCs by modulating PAMP-induced stimulation of immune responses (84, 85). 
However, multiple groups have argued that HSPs in fact counteract inflammatory responses 
(85-88). Death by necrosis, unlike normal apoptotic cell death, leads to a degradation of the 
cell membrane and release of intracellular DAMPs, damage associated molecular patterns 
(89). Necrotic cells have been shown to activate DCs and release HSPs (82, 90). 
1.2.3 Mucosal adjuvants 
 
Commonly studied exogenous adjuvants include TLR agonists, mutant bacterial 
enterotoxins, and viral vectors. For example, Salmonella and reovirus are known to target M 
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cells, and work is being done to attenuate them to act as targeted antigen delivery vehicles 
(91-93). TLRs activate innate immunity to produce inflammatory cytokines and APC 
costimulatory molecules (93). Unmethylated CpG dinucleotides like those found in bacteria 
have been used as adjuvants to activate TLR9 and induce Th1 immune responses (94). 
Components of bacterial cell walls such as LPS stimulate antigen presenting cells through 
TLR4 (95). Bacterial endotoxins such as cholera toxin (CT) have been mutated to remove 
toxicity, but maintain adjuvanticity to induce humoral and cell-mediated immune responses 
(96, 97). For example, our group has studied a mutated cholera toxin in which ADP-
ribosylating activity and toxicity was removed (98). CT-2*, as it is called, has been shown to 
induce T helper (Th) and CTL responses after intranasal immunization with antigen, as well 
as Th1 responses in both mucosal and systemic compartments, while avoiding tolerance 
induction (99, 100). These adjuvants fall under the subgroup of adjuvants that interact 
directly with the innate immune system to enhance immunity. The latter subgroup 
encompassing carrier adjuvants, including ISCOMs, liposomes, chitosan, and viral vectors, 
has been previously discussed. 
 
1.3 α-GALACTOSYLCERAMIDE AND INVARIANT NKT CELLS 
1.3.1 α-GalCer Structure 
  
First discovered by the Koezuka group at the Kirin Brewing Company in Japan in 
1993, alpha-galactosylceramide (α-GalCer) is a glycosphingolipid originally synthesized 
based on agelasphins isolated from the sea sponge Agelas mauritanius when it was 
screened for the presence of antitumor compounds against liver metastases (101, 102). 
Most glycosphingolipids in mammals are beta-linked. The main difference between these 
mammalian ceramides and α-GalCer is that α-GalCer lacks the double bond between 
sphingosine carbons 4 and 5 and has an extra hydroxyl group on carbon 4 (Figure 1) (103). 
Additionally, naturally occurring ceramides contain unsaturated bonds, whereas α-GalCer is 
fully saturated (104). Studies showing that small molecule attachments to the C6 of the 
galactose ring do not interfere with α-GalCer activity (105) have allowed attachment of small 
fluorophores at this site to accommodate trafficking studies (106). 
  
 Figure 1. Structure of α-Galactosylceramide (
 
 
Figure 1. α-GalCer is a glycosphingolipid that consists of a sphingosine base, fatty acyl 
chain and an α-anomeric sugar moiety.
binds the glycosyl head. This figure is adapted from 
Funakoshi/DiagnoCine (Hackensack, NJ
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α-GalCer). 
 The CD1d binds the lipid portion and the NKT TCR 
α-GalCer Data Sheet from 
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1.3.2 α-GalCer modulates NKT cell activity 
α-GalCer potently activates the innate immune-mediating invariant natural killer T 
cells (NKT) which play a role in controlling adaptive immunity (107-109). NKT cells were 
originally identified by 3 independent groups (110). In 1986, Taniguchi and co-workers 
discovered that 90% of their independent T cell suppressor hybridomas expressed Vα14 
and Jα281 genes (111, 112). Furthermore, in various mouse strains with different MHC 
haplotypes, they found that these Vα14+ cells were fewer in number in β-2-microglobulin 
deficient mice, which don’t express MHC class I or its related molecules, indicating a 
monomorphic MHC class I-like receptor (113, 114). They additionally showed that these 
Vα14+ cells were able to develop in extrathymic lymphoid tissues, like bone marrow and 
liver, but not in the spleen (115). In the second study in 1987, Fowlkes and Budd found a 
CD4-CD8- thymocyte population that expressed Vβ8 only (116, 117), which was later found 
to also express NK1.1, CD5, and CD44 (118, 119) as well as both Th1 and Th2 cytokines 
(120, 121). Finally, the third study carried out by Bendelac’s group in 1994 established a 
hybridoma line of Vβ8+CD5highCD44+ cells which were found to express mRNA for Vα14 
(122). This group also found that these hybridomas recognized the MHC I-like monomorphic 
CD1d molecule (123, 124). Thus the invariant NKT cell population was identified. 
As previously mentioned, invariant NKT cells are termed as such because they 
express a single form of Vα TCR, in mice Vα14-Jα18, and in humans Vα24-Jα18, as well as 
NK cell markers such as NK1.1, and are even able to perform killing functions similar to NK 
cells (110, 125-129). As some CD8+ T cells have been found to express NK cell markers 
and expression levels of NK markers vary in NKT cells (130, 131), NKT cells are now 
restricted to those cells whose TCRs respond to CD1d. In fact, even NK1.1 negative cells 
are considered to be NKT cells as long as they are CD1d restricted (128). CD1d- dependent 
NKT cells expressing invariant TCR can be found mainly in the liver as well as the omentum 
lining the abdomen in humans (132), while CD1d-independent NKT cells expressing a 
variety of TCRs are found in the spleen and bone marrow (133). CD1d-independent NKT 
cells are activated by DCs responding to bacterial components via TLRs, as well as directly 
through exposure to IL-12 and IL-18 (134, 135). Invariant NKT cells are functionally diverse 
based on their anatomic locations (136-138). Depending on the tissue in which the NKT 
cells are located, they can be regulated by different factors; for example, liver NKT cell 
numbers depend on CXCR6, LFA-1, and transcriptional regulator ID2 (139-144), whereas 
NKTs in the thymus and spleen are not dependent on these factors (139). Interestingly, NKT 
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cells are highly evolutionarily conserved as evidenced by the fact that mouse cells can 
recognize human CD1d+antigen, and vice versa (139, 145-147). CD1d preferentially 
presents lipid, binding to the saturated hydrocarbon chains in the galactose ring of α-GalCer 
(148). Most NKT antigens contain a lipid tail that binds CD1d and a sugar head that binds to 
the NKT TCR (147, 148). Furthermore, the stability of the TCR:α-GalCer:CD1d complex is 
determined by the length of the phytosphingosine chain (147, 149). CD11c+ DCs interact 
with the NKT cells through antigen presentation and CD40-CD40L interaction to activate the 
NKT cells (109, 150). When activated, NKT cells produce large amounts of IFNγ and IL-4, a 
phenomenon known as a cytokine storm. This storm can influence responses against 
tumors and even autoantigens, and is responsible for the role of NKT cells in inducing 
adaptive immune responses (109, 151, 152). Additionally, NKT cells play a role in innate 
immunity as they are equipped with cytotoxic capabilities from perforin, granzyme, tumor 
necrosis factor (TNF)-α, Fas ligand, and TNF-related apoptosis-inducing ligand (TRAIL) 
(147, 151, 153, 154). These NKT cells have been shown to play roles both in controlling and 
suppressing anti-tumor immune responses, as well as contributing to asthma but protecting 
against autoimmune disease (155). The NKTs playing a protective role have been shown to 
be mainly CD4- classical invariant, or type I, while suppressive NKTs are mainly CD4+, or 
type II. Alternatively, others have shown that α-GalCer is able to activate CD4+ NKT cells 
which activate NK cells and produce cytokines (150). The rapid response by these cells has 
been attributed to the existence of pre-formed mRNAs for various cytokines including IFNγ, 
IL-4, and IL-13 (139, 156-160). Classical type I (invariant NKT) cells are known to make IL-4 
within two hours of α-GalCer administration, and IFNγ within 6 hours; these are the cells that 
play a role in asthma in both mice, and less so, in humans (155, 161-163). Type II NKT cells 
express a more diverse array of TCRs and do not respond to α-GalCer, while responding to 
other lipids presented on CD1d. They were found first in MHCII deficient mice in the CD4+ 
population and also in a tumor negative for MHC I or II (155, 164, 165). These type II NKT 
cells are much less well understood, and functions identified include a suppressive role in 
EAE (166) and diabetes mellitus in NOD mice (167). 
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1.3.3 NKT cells and anti-tumor immunity 
NKT cells were first implicated in immunity when the same group that discovered α-
GalCer found that injection of the compound afforded protection against tumor development 
and metastasis (168-170). This protection was linked to IFNγ production and NK cell 
activation (Figure 2) but not to perforin from the NKT cells, leading to the conclusion that 
NKT cells act as mediators of the immune response rather than direct killers (171-173). The 
cells were identified to be CD4- and CD8-, consistent with reports in humans showing that 
double negative NKT cells are prone to produce Th1 cytokines (e.g. IFNγ) (136, 137, 155, 
174). Dendritic cells were soon tied to the evolving mechanistic picture of NKT cells when it 
was shown that pulsing DCs with α-GalCer led to better protective responses by NKT cells 
(175) and that after interaction with NKT cells, the mature DCs produced IL-12 and IL-15 
and enhanced T cell responses (31). Thus, DCs loaded with α-GalCer were examined for 
their ability to fight tumor progression  in both mice (176) and humans (177-182). Studies 
have gone further to expand NKT cells in vitro with α-GalCer-pulsed DCs or with α-GalCer 
and IL-2 in clinical trials (183, 184). However, these studies did not lead to conclusive 
results of beneficial effects using these treatment methods. In contrast to the protective 
effect conferred by NKT cells, it was discovered that NKT cells can also play an immune 
suppressive role in tumorigenesis and autoimmunity. Two tumor models testing NKT cell-
mediated responses in CD1d knock-out mice revealed that tumors did not recur or 
metastasize in the absence of NKT cells; this tolerogenic effect of NKT cells was linked to 
their production of IL-13 rather than IL-4 (185-187). Further studies utilizing α-GalCer and 
sulfatide (166) to selectively activate NKT type I and type II cells, respectively, revealed that 
indeed NKT type I cells activated by α-GalCer and even the lesser agonist OCH, which 
skews to Th2 responses (188), confer protection while activation of type II NKT cells 
suppress, an effect abrogated by depletion of CD4+ T cells (189). Furthermore, activation of 
NKT cells in vitro with both α-GalCer and sulfatide simultaneously revealed a decrease in 
proliferation normally induced by α-GalCer (189). In mouse models, administration of α-
GalCer followed shortly by sulfatide resulted in reduction or complete elimination of 
protective effect (189). These studies revealed a new level of immune regulation by NKT 
cells in tumorigenesis, and may play a role in the adaptive responses induced by activation 
of NKT cells. 
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1.3.4 NKT cells, costimulation, and anergy 
Conventional T cells are activated by a series of signal inputs, starting with signal I 
which encompasses the interaction of MHC-antigen complex with the TCR, and signal 2, or 
the costimulatory signal, when CD28 interacts with B7.1 or B7.2 on pAPCs (147, 190). In the 
absence of signal 2, signal 1 will induce anergy in T cells. In the presence of both signals, T 
cells go through changes to promote survival and growth. In contrast, negative costimulatory 
molecules exist including cytotoxic T lymphocyte-associated antigen (CTLA)-4, programmed 
death (PD)-1, and B and T lymphocyte attenuator (BTLA) (191). NKT cells also express 
costimulatory molecules, but they exist in a pre-activated state, even in germ-free mice 
(192). Given the presence of pre-formed mRNAs, it is possible that NKT cells have a lower 
activation threshold. In addition, upon activation, NKT cells proliferate and quickly produce 
cytokines, but this is followed by cell death and a phenotypic state known as anergy (193). 
Anergic NKT cells do not respond to re-exposure to α-GalCer by proliferating or producing 
IFNγ, but they do retain some ability to produce IL-4. The involvement of costimulatory 
signals in activation and anergy of NKT cells remains to be elucidated. However, given its 
vital role in T cell activation, CD28 has been studied extensively in NKT cells. CD28 and 
B7.1/B7.2 (CD80 and CD86, respectively) knockout mice both experience a decrease in 
NKT cell numbers of greater than 50% (194-196). CD28 is also important in the maturation 
process as measured by expression of surface markers such as NK1.1, CD69, and 
intracellular IFNγ (194, 195), whereas overexpression studies have revealed defective NKT 
cell development (194). Finally, blocking of B7.2 (CD86) decreased IFNγ production in α-
GalCer-stimulated splenocytes, more so than blocking IL-4 and B7.1, indicating that this 
interaction may play a role in skewing NKT cells toward Th1 responses (197). PD-1 acts as 
a coinhibitory receptor in T cells (198) and is associated with a phenotype of functional 
exhaustion. PD-1 has been shown to be dispensable for NKT cell development in both 
single and double knockout mice for its two ligands, PD-L1 and PD-L2. However, PD-1 is 
upregulated after a single treatment of α-GalCer and remains so in anergic NKT cells. It has 
been shown that blocking the PD-1/PD-L(1 or 2) interaction avoids anergy, but that blocking 
PD-1/PD-L1 does not reverse established anergy in vivo (199). The involvement of PD-1 in 
anergy induction appears to be exclusive to α-GalCer-induced anergy, as anergy was 
induced by heat inactivated Escherichia coli or sulfatide regardless of PD-1/PD-L1 
interaction blockade (199). Additionally, in a melanoma challenge model, where multiple 
doses of α-GalCer exacerbated metastasis as compared to one dose and even vehicle, co-
administration of α-GalCer with anti-PD-L(1 and 2) enhanced anti-metastatic effects (199). 
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When activated, NKT cells express CD40L (200, 201) which interacts with CD40 on DCs, 
activating them to produce IL-12 (150, 201). IL-12 stimulates NKT cells to produce IFNγ, 
though it has been shown that IL-12 is dispensable for IL-4 production by α-GalCer-
activated NKT cells (150, 200, 202). This may be why DC-NKT interaction skews to Th1 
response. In fact, in CD40 knockout mice, α-GalCer no longer exhibits anti-metastatic 
properties (200). Each of these costimulatory factors points to an additional method to target 
α-GalCer treatments for improved immune responses.   
  
 Figure 2. Natural killer T cells interact with many different cell types.
Figure 2. Invariant natural killer T (iNKT) cells 
and T cells to modulate immune activity. These interactions are reciprocal between the APC 
and iNKT cell. Signaling utilizes the CD1d
the interactions of CD40, CD27, and OX40 with their ligands, and cytokine release. This 
figure is adapted from Figure 1, Cerundolo V. et al, Nat Rev Immunol 2009.
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1.3.5 α-GalCer Analogues 
 
Structural, kinetic, and functional studies are being conducted to identify NKT cell 
agonists that possess the optimal qualities of an NKT cell-activating vaccine adjuvant. The 
structure of α-GalCer is composed of a hydrophilic carbohydrate head connected via alpha-
linkage to the hydrophobic ceramide or lipid portion (Figure 3). The ceramide portion is 
made up of a long fatty acyl chain that is 26 carbons long as well as an 18-carbon long 
sphingosine chain (110). Studies have concluded that the stability of the lipid-CD1d complex 
is affected by the length of the acyl and sphingosine chains, that saturation of the alkyl 
chains plays a role in lipid dissociation from CD1d, and that the length of the lipid chain 
modulates the TCR binding to the lipid-CD1d complex (149, 203). For example, unsaturated 
acyl chains form a kink which helps binding to CD1d and allows presentation by non-
professional APCs and skewing towards Th2 responses (203-206). Functional studies have 
shown that a shortened length of either the acyl or sphingosine chains leads to a reduction 
in NKT cell proliferation (110, 145). Specifically, treatment with the α-GalCer analogue 
OCH9, with its shortened 9-carbon long sphingosine chain (Figure 3), resulted in more IL-4 
secretion than α-GalCer and successfully treated EAE (188, 203, 207), (188, 208). In further 
studies, OCH was shown to be beneficial in treating other autoimmune diseases such as 
collagen-induced arthritis (209), and type I diabetes (210). Teyton’s group subsequently 
showed that OCH is primarily presented by B cells (208, 211). Substituting the acyl chain of 
α-GalCer C26:0 (26 carbons, 0 unsaturated) with the shortened and di-unsaturated C20:2 
acyl chain induced Th2 polarized immune responses with less IFNγ and NKT cell 
proliferation (93). Other important functional moieties include the 2’-hydroxyl of the sugar 
head and the 3’-hydroxyl of the sphingosine chain, as changes at these locations using α-
mannosylceramide and α-GalCer lacking the 3’-hydroxyl did not activate NKT cells (110, 
145, 203). Three hydrogen bonds at the junction of the carbohydrate head and ceramide tail 
“anchor” α-GalCer into the binding groove of CD1d (212). Another analogue, α-C-GalCer, 
has a CH2 methylene instead of O at the 1’ position (Figure 3) and was found to produce 
more prolonged responses and higher IFNγ production, as much as 1000 times higher than 
α-GalCer, in mouse models of malaria and metastatic melanoma, perhaps by protecting the 
CD1d-lipid complex from enzymatic degradation (203, 208, 213). Threitolceramide (ThrCer), 
an analogue of α-GalCer lacking a sugar head and containing non-glycosidic linkages 
between the sugar head and ceramide portions (Figure 3), stably binds CD1d and is 
capable of forming the three hydrogen bonds formed by α-GalCer and CD1d (203, 214). It 
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has been shown that ThrCer can activate antigen-specific B and T cell immune responses 
similarly to α-GalCer, but does not induce NKT cell-dependent lysis of DCs, perhaps due to 
weaker binding to the TCR (214). Additionally, it was shown that while after 7 days, a 
second injection of ThrCer did not induce IFNγ production by NKT cells, this ability had 
recovered by day 14, indicating that induction of anergy is in some way determined based 
on either the affinity of the antigen for CD1d, or the on and off rates of the CD1d-glycolipid 
complex with the NKT TCR. 
  
 Figure 3. Synthetic α-GalCer analogues.
α-GalCer analogues with vary
anomeric linkages, and carbohydrate heads
et al, Nat Rev Immunol 2009. 
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In addition to analogue studies, scientists have been searching for endogenous 
antigens of NKT cells, without which NKT cells would not exist. A study by Stanic et al 
revealed that a cell line lacking beta-D-glucosylceramide synthase could not stimulate NKT 
cells, while mice lacking beta-galactosylceramide have intact and functional NKT 
populations (163, 208). Another study by Zhou et al showed an NKT cell deficiency in mice 
lacking beta-hexosaminidase B, which is responsible for cleaving globosides to 
isoglobosides, specifically Gb4 to iGb3 including intermediate steps (105). They then 
showed that iGb3 stimulated NKT cells, but none of the precursors did so, thus revealing an 
endogenous antigen potentially playing a role in NKT positive selection. This stimulation is 
different from that caused by LPS, in which DCs are activated to release IL-12, which then 
transactivates NKT cells (208, 215, 216). Other exogenous antigens have been elucidated. 
For example, studies by Fischer et al revealed that the PIM4 glycolipid from mycobacteria 
can modestly stimulate NKT cells, while PIM2 which has two fewer sugars does not, 
revealing that the NKT TCR can recognize sugars distal from the antigen portion bound to 
CD1d (217). 
1.3.6 Repeated activation of NKT cells 
 
In 2011, our report in the European Journal of Immunology presented evidence that, 
in contrast to systemic immunization, two doses of α-GalCer admixed with Ova antigen via 
the intranasal route allow for repeated activation of NKT cells in the lung and lung-draining 
lymph nodes as well as induction of Ova-specific T cell responses (218). These studies 
explore the potential mechanism behind our 2009 publication in which multiple doses of α-
GalCer by the intranasal or oral routes induced systemic and mucosal immune responses. 
In the previous study, we characterized the NKT cell response as a mediator of the 
observed adaptive immune responses reported previously. We observed that a single dose 
of intranasal α-GalCer resulted in a peak of IFNγ production in the lungs of mice 1 day post-
immunization, which corresponded with an expansion of the NKT cell population that 
peaked at 5 days post-immunization. A second intranasal dose of α-GalCer again resulted in 
a peak of IFNγ one day post-secondary immunization and corresponded to a second 
expansion of the NKT cell population which peaked 5 days after the second dose. Results 
from each consecutive dose corresponded with an increase in CD86 expression by DCs 
above Ova alone control 1 day after each dose was delivered. Additionally, two doses of α-
GalCer were shown to be necessary to induce significant antigen-specific CTL responses as 
21 
 
well as antigen-specific IFNγ-producing CD8+ T cells. To study whether the tissue of origin 
plays a role in the lack of NKT cell anergy induction, multiple tissues including spleen, lung, 
and lung draining lymph nodes were co-cultured with the NKT cell clone DN32.D3 and 
subsequent IL-2 production was measured. Strong activation of the clones when co-cultured 
with cells from the lung and mediastinal lymph node indicated that these tissues are the site 
of α-GalCer presentation after intranasal immunization. To characterize the cellular 
phenotype of the APC responsible for α-GalCer presentation in the lung, we performed bead 
isolation of CD11c+ and B220+ cell populations after intranasal immunization with α-GalCer, 
and isolated cells were co-cultured with the NKT cells clones. Only CD11c+ cells from mice 
immunized with α-GalCer induced IL-2 production by the NKT cell clones. Additionally, we 
examined the expression of PD-1, as upregulation of this marker for functional exhaustion 
has been associated with NKT cell anergy induced by systemic immunization with α-GalCer. 
There was no increase in PD-1 expression after a single intranasal dose of α-GalCer as 
compared to Ova alone, in contrast to a sharp increase in PD-1 expression after a single 
dose of intravenous α-GalCer. These results indicated a difference in functional competence 
of NKT cells between systemic and mucosal α-GalCer delivery, while also highlighting the 
necessity for multiple intranasal doses of α-GalCer to induce cellular immune responses. 
These studies served as the backbone of the studies in this thesis in which we explore the 
effects of combining intranasal and intravenous immunization routes on the induction of NKT 
cell anergy and subsequent adaptive immune responses. 
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CHAPTER 2: STATEMENT OF OBJECTIVES 
 
Adjuvants are an indispensable part of vaccine formulations as they act to enhance 
adaptive immune responses to co-administered antigens. This is particularly important for 
vaccinations that target the tolerogenic mucosal tissues, which serve as the main portal of 
entry into the body for many pathogens. However, there are no mucosal adjuvants approved 
by the FDA. Adjuvants possess the capacity to bridge innate and adaptive immunity through 
activation of innate immune mediating cells such as invariant natural killer T cells (NKT). 
Alpha-Galactosylceramide (α-GalCer) is a synthetic glycolipid that selectively activates NKT 
cells, making it an attractive candidate to serve as an adjuvant in peptide and protein 
vaccines. We previously reported that α-GalCer delivered by the intranasal route is able to 
reactivate NKT cells to produce IFNγ and downstream adaptive responses after multiple 
immunizations, which contrasts with the trend seen after systemic immunization in which a 
single administration of α-GalCer results in anergy of responding NKT cells. In the present 
investigation, I tested the hypothesis that the differential capacity of NKT cells to 
produce IFNγ in response to α-GalCer immunization, as based on the route of 
immunization, influences the adjuvant effect of α-GalCer and, thus, the induction of 
adaptive responses. I obtained evidence that significant production of IFNγ production 
after each immunization may be dispensable for inducing adaptive immune responses. In 
addition, I found that multiple intranasal immunizations beyond two doses may in fact be 
inducing NKT cell anergy, but at a slower rate than the systemic counterpart. The following 
specific aims were designed to examine the central hypothesis that IFNγ production by NKT 
cells plays an important role in harnessing the adjuvant effects of α-GalCer. 
 
Specific Aims 
Aim 1: Determine the influence of combining routes on activation of NKT cells. Mice 
were immunized by the intranasal or intravenous routes with a combination of α-GalCer and 
ovalbumin (Ova) protein. Mice were immunized by one of the four following regimens: IV-IV 
or IV-IN, IN-IN-IN or IN-IV-IN. Adaptive immunity was measured using the IFNγ Elispot 
assay to enumerate antigen-specific IFNγ-producing cells in various tissues. 
Aim 2: Determine the role of NKT cell reactivation and subsequent DC activation in 
enhancing adaptive immunity. Cells from mice following the above immunization schemes 
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were fluorescently stained to enumerate and determine activation levels of the NKT cell and 
dendritic cell (DC) populations using flow cytometry. Additionally, another group of mice was 
delivered four sequential doses of α-GalCer intranasally to determine if anergy is onset via 
this route after multiple immunizations. Adaptive responses were measured using IFNγ 
Elispot, and sequential intranasal immunizations with α-GalCer were further tested using a 
mouse model of HPV, utilizing α-GalCer and HPV peptides corresponding to conserved 
regions of the E6 and E7 HPV-16 oncoproteins found in cervical neoplasia.  
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CHAPTER 3: MATERIALS AND METHODS 
 
3.1 ANIMALS 
Female C57BL/6 mice 6-10 weeks of age were purchased from the National Cancer 
Institute (Bethesda, MD) and maintained in a specific pathogen-free environment at The 
University of Texas M.D. Anderson Cancer Center. All procedures were carried out in 
accordance with institutionally approved protocols. The animal facility is fully accredited by 
the Association for Assessment and Accreditation of Laboratory Animal Care International, 
and studies were conducted according to National Institute of Health Guidelines on the Care 
and Use of Laboratory Animals. 
 
3.2 CELL LINES AND CELL CULTURES 
The TC-1 tumor cells are primary lung epithelial cells of C57BL/6 mouse origin that 
were transfected to express the E6 and E7 oncogenes of HPV-16 as described earlier (219) 
and were a kind gift from Dr. T.-C. Wu, Johns Hopkins Medical Institution, Baltimore, MD. 
The TC-1 cells were grown in RPMI supplemented with 10% heat-inactivated FBS, 400 
ug/ml of G418. The EG7·Ova cells are EL-4 thymoma cells transfected with chicken 
ovalbumin (220) and were a kind gift from Dr. Chen, Dept. of Immunology, UT MD Anderson 
Cancer Center. They were maintained in DMEM supplemented with 10% heat-inactivated 
FBS, 2 mM glutamine, 100 U/ml penicillin, 100 ug streptomycin, and 400 ug/ml G418. 
 
3.3 PEPTIDES AND REAGENTS 
Synthetic Ova peptide corresponding to the CTL epitope of chicken ovalbumin 
(SIINFEKL) was purchased from Peptides International Inc. (Louisville, KY) and dissolved in 
1XPBS at a concentration of 2.5mg/ml. Ova protein was purchased from Sigma (St Louis, 
MO) and re-suspended in 1x phosphate-buffered saline (PBS; Gibco, Carlsbad, CA) at 
40mg/ml. 
The synthetic glycolipid activator of NKT cells, α-GalCer or KRN7000, was 
purchased from Diagnocine LLC (Hackensack, NJ) and dissolved in dimethyl sulfoxide 
(DMSO; Sigma, St Louis, MO) to a concentration of 1mg/ml.  
Custom peptides corresponding to CD8 epitopes of the E6 and E7 oncoproteins of 
HPV-16 were obtained from GenWay Biotech (San Diego, CA) at a purity of >95%. E643–57 
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peptide, Q15L (QLLRREVYDFAFRDL), and E744–62 peptide, Q19D 
(QAEPDRAHVYNIVTFCCKCD) were modified to include upstream amino acids in order to 
facilitate purification, yielding (KQQLLRREVYDFAFRDL) and 
(GQAEPDRAHYNIVTFCCKCD), respectively. Peptides were resuspended at 3% and 5% 
DMSO to concentrations of 5mg/mL and 10mg/mL, respectively. 
 
3.4 IMMUNIZATIONS 
For dosing scheme experiments, mice were immunized by the intranasal or 
intravenous route 1-4 times at 5 to 7 day intervals, as described per experiment, following 
the procedures reported earlier (221): Mice received Ova protein alone (at 100 
ug/mouse/dose) or admixed with the adjuvant synthetic glycolipid α-GalCer (at 2 
ug/mouse/dose), diluted in PBS to 20ul or 200ul respectively) (10ul/nostril). For tumor 
challenge experiments, mice were immunized by the intranasal route, twice at 5-day 
intervals before TC-1 challenge or 2-3 times at varying intervals post-tumor challenge, with a 
mixture of the Q19D and Q15L peptides (100 ug of each/mouse) along with either CT (1 
ug/mouse) or α-GalCer (at 2 ug/mouse) in a volume of 15 ul/nostril diluted in PBS. For all 
immunizations, mice were anaesthetized by the intraperitoneal (IP) injection of a ketamine-
xylazine mixture (10mg/mL ketamine and 1mg/mL xylazine in bacteriostatic water), with 
volume ranging from 100-200 uL/mouse based on weight. At various time-points post 
immunization, mice were sacrificed and cell suspensions were prepared from the spleen by 
homogenization and from the lung, liver and lymph nodes by enzymatic dissociation for one 
and a half hours by incubation with 1 mg/mL collagenase type IV (Sigma, St. Louis, MO) 
solution re-suspended in complete RPMI medium. Lungs were perfused with 10 mL of 1x 
PBS prior to tissue collection. Lymphocytes from liver were further isolated by centrifugation 
through a percoll (Sigma, St. Louis, MO) gradient where 44% and 67% percoll solutions 
were made with serum free RPMI. Cells were suspended in the 44% percoll solution and the 
67% percoll solution was layered below using a 14 gauge pipetting needle (Fisher Scientific, 
Waltham, MA). The solution was then centrifuged for 20 minutes at 2700 rpm, and the 
interphase was collected and washed in RPMI. Red blood cells were removed by incubation 
with ACK lysing buffer (1ml per pellet) for 5 minutes (Lonza Bioscience, Basel, Switzerland), 
which was then inactivated with 5ml complete RPMI. 
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3.5 IFNγ ELISPOT ASSAY 
Cells isolated from spleen, liver, lung and mediastinal lymph nodes (MdLN) of 
immunized mice were subjected to Elispot assay to enumerate antigen specific IFNγ-
producing cells as described earlier (221) using the reagent kit from BD Biosciences (San 
Jose, CA). The spots on the membrane, representing individual IFNγ-producing cells as spot 
forming colonies (SFC), were enumerated by the independent agency Zellnet Consulting 
Inc., New York, NY using the KS-ELISPOT automatic system (Carl Zeisis Inc., Thornwood, 
NY). Responses were considered positive when they were above 10 SFC/well and at least 
double the number obtained in cells cultured with medium alone. 
 
3.6 FLUORESCENCE LABELED ANTIBODIES AND FLOW CYTOMETRY 
Single-cell suspensions isolated from the various tissues of immunized mice were 
analyzed for the phenotype and function of NKT cells by flow cytometry. All the reagents, 
unless otherwise mentioned, were purchased from BD Biosciences, San Jose, CA. The NKT 
cells were stained first with Aqua Live/Dead reagent (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. Cells were then washed and incubated with 
APC-conjugated mouse CD1d tetramer loaded with PBS57 (provided by NIAID tetramer 
facility at Emory University, Atlanta, GA, USA) at a concentration of 0.25ul in 50ul 1x PBS 
for 30 min in the dark at 37°C. Cells were then additionally incubated with a combination of 
surface markers, Pacific Blue-conjugated CD3 (clone 500A2, BD Biosciences), FITC-
conjugated PD-1 (clone J43, eBioscience, San Diego, CA,USA), and PE-Cy7 CD69 
(H1.2F3, eBiosciences) for an additional 30 min at 4°C in the dark. Cells were then washed 
and fixed in 100ul of 4% Paraformaldehyde diluted in 1x PBS for 10 min at 0°C in the dark. 
The percentages of DCs and their activation status were analyzed by staining for FITC-
conjugated CD11b (clone M1/70, BD Biosciences), APC-conjugated CD11c (clone HL3, BD 
Biosciences), and PE conjugated CD86 (clone GL1, BD Biosciences) for 30 min at 0°C. 
After staining, all cells were analyzed on an LSRII flow cytometer (BD Biosciences) and the 
data was analyzed using FlowJo software (Tree Star, Ashland, OR, USA). For NKT cell 
analysis, lymphocytes were first gated using the forward scatter and side scatter plots. Next, 
live cells were gated using side scatter and Aqua plots. Finally, the NKT cell population was 
determined by plotting PB-CD3 against the CD1d tetramer and these cells were analyzed 
further for surface marker expression and cytokine production. For DC analysis, cells were 
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first gated using the forward scatter and side scatter plots. Next CD11c+CD11blow cells were 
gated and then CD86 expression was determined by histogram plots. 
 
3.7 INTRACELLULAR CYTOKINE STAINING 
For intracellular cytokine staining all cells were incubated with GolgiPlug (1ul/well in 
200ul complete RPMI) (BD Biosciences, San Jose, CA) for 4.5 hours at 37°C before any 
cellular staining. Cells were stained for surface markers and fixed as described above. Cells 
were then washed and incubated with cytokine antibodies in 1x BD Perm/Wash Buffer (BD 
Biosciences, San Jose, CA) for 60 minutes at 4°C. The cytokine specific antibody used in 
these experiments was PE-conjugated anti-IFNγ (clone XMG1.2, BD Biosciences, San Jose, 
CA). Cells were then washed two more times in the Perm/Wash buffer and resuspended in 
PBS containing 5% FBS, and samples were analyzed on the LSRII as described above.   
 
3.8 STATISTICAL ANALYSIS 
The data were analyzed for statistical significance using the student’s t-test for paired 
samples and a p-value of <0.05 was considered significant. Statistical significance between 
immunizations routes was calculated using two-way ANOVA of repeated measures, and a p-
value of <0.05 was considered significant. Data shown is representative of results obtained 
from individual experiments. 
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CHAPTER 4: RESULTS 
 
4.1 EFFECT OF α-GALCER WHEN DELIVERED VIA THE IV-(IV/IN) SCHEME 
 
It is known that a single administration of intravenous α-GalCer strongly activates 
NKT cells to produce IFNγ and IL-4 (193). We and others have reported that these 
responses exert a potent adjuvant effect by strongly promoting adaptive humoral and 
cellular immune responses to co-administered antigen. However, it has also been shown 
that immunization with α-GalCer by the systemic intravenous route results in NKT cell 
anergy, a state in which a subsequent dose of α-GalCer does not activate NKT cells to 
produce IFNγ and does not lead to induction of an adaptive T cell response. In contrast, our 
previous studies have shown that multiple doses of α-GalCer can be administered via the 
intranasal route resulting in the reactivation of NKT cells to produce IFNγ and improved 
adaptive immune responses with each additional dose, up to a total of three tested. We 
therefore hypothesized that the route of α-GalCer delivery influences whether or not NKT 
cells develop anergy and that repeated activation of NKT cells and the production of IFNγ 
are important for the sustained adjuvant effect observed after mucosal (intranasal) versus 
systemic (intravenous) administration of α-GalCer. We investigated whether use of a 
combination of the intravenous and intranasal routes for the administration of α-GalCer 
could circumvent the induction of NKT cell anergy, thus allowing repeated activation and 
IFNγ production to facilitate sustained and/or improved adaptive immune responses to co-
administered antigen.  
We first tested whether administration of Ova (+/- α-GalCer) by the intravenous route 
followed by a second intranasal dose (IV-IN regimen), versus a second intravenous dose 
(IV-IV regimen), would reactivate NKT cells to produce IFNγ and elicit sustained and/or 
stronger Ova-specific adaptive T cell responses. As shown in Figure 4, separate groups of 
mice were administered the first dose of Ova (+/- α-GalCer) by the intravenous route. One 
day later, one set of mice was sacrificed and single cell suspensions from the spleen, liver, 
lung, and lung-draining mediastinal lymph node (MdLN) tissues were analyzed to determine 
NKT and dendritic cell responses. The second group of mice received a second dose of Ova 
(+/- α-GalCer) by the intranasal route five days after the first dose (IV-IN regimen). From 
among these, one set of mice was sacrificed on day six (one day after the second dose) to 
measure NKT cell responses as well as adaptive immune responses to the first round of 
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immunization by the IV route, specifically IFNγ production by CD8+ T cells in response to in 
vitro stimulation with an Ova-specific CD8+ T cell epitope peptide. Finally, a third group of 
mice was sacrificed on day twelve, which was seven days after the second round of 
immunization by the IN route, to measure adaptive immune responses subsequent to the 
second intranasal dose of Ova (+/- α-GalCer). In parallel, additional groups of mice were 
administered a second dose of Ova (+/- α-GalCer) by the intravenous route (IV-IV regimen) 
and subjected to similar analyses. Using fluorescently labeled antibodies and flow 
cytometry, NKT cells were identified and analyzed for activation in terms of production of 
IFNγ and expression of CD69 and PD-1. First, lymphocytes were gated using a forward 
scatter versus side scatter plot. Next, live cells were gated using a side scatter versus Aqua 
live/dead staining. The live lymphocytes were then gated using CD3-Pacific Blue versus 
CD1d Tetramer-APC staining to identify the double positive population as the NKT cells 
(Figure 4 B). The NKT cells were further analyzed for production of IFNγ as an indication of 
functional activation. We also analyzed the IFNγ positive population for the expression of 
CD69 activation marker using anti-CD69-PECy7 antibody and PD-1 anergy marker using 
anti-PD-1-FITC antibody. Additionally, dendritic cells were analyzed by flow cytometry after 
staining for the CD11c+ population to characterize expression of CD86 by mean 
fluorescence intensity (MFI) histogram. Finally, the adaptive cellular immune responses to 
the co-administered Ova antigen were analyzed by the IFNγ Elispot methodology employing 
the Ova-specific CD8+ T cell epitope peptide.  
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Figure 4. Immunization scheme and gating strategy for flow cytometry analyses of 
NKT and dendritic cells. (A) Mice were immunized with Ova +/- α-GalCer first by the 
intravenous route followed by second immunization either by the intravenous or intranasal 
route at day 5 after the primary immunization. Mice were sacrificed on days 1, 6, and 12 
post-primary immunization. (B) Single cell suspensions prepared from the spleens, lungs, 
livers, and mediastinal lymph nodes of immunized mice were stained with fluorescently 
labeled reagents to detect NKT cells using: anti-CD3-PB, CD1d tetramer-APC, anti-IFNγ-
PE, and Aqua live/dead stain. Aqua live/dead stain, anti-CD3-PB, CD1d Tetramer-APC, 
anti-IFNγ-PE, anti-PD-1-FITC, and anti-CD69-PECy7. The gating strategy for enumerating 
live CD1dTet+CD3+ cells expressing PD-1, CD69, and IFNγ is shown. (C) The dendritic 
cells isolated from the spleens, lungs, livers, and mediastinal lymph nodes were identified by 
staining with fluorescently labeled anti-CD11b-FITC, anti-CD11c-APC, and anti-CD86-PE to 
enumerate CD11blowCD11c+ dendritic cell population and to measure activation by CD86 
expression. Gating strategy is shown. Panels show a representative spleen from a mouse 
that received aGC+Ova by the intranasal route.  
  
 Figure 4. Immunization scheme and gating strategy for flow cytometry analyses of 
NKT and dendritic cells. 
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4.1.1 Analyses of cells from the spleen 
 
A single IV dose of α-GalCer elicited strong activation of NKT cells in the spleen as 
evidenced by potent IFNγ production, PD-1 expression, and significant CD69 expression 
(Figure 5 A,B,C). Concurrently, we observed strong activation of DCs as measured by CD86 
expression (Figure 5 D). We also observed significantly higher levels of adaptive immune 
response in terms of Ova peptide-specific IFNγ producing cells in mice that received α-
GalCer+Ova relative to those that received Ova alone (Figure 5 E). Mice administered a 
second IV immunization of α-GalCer+Ova (IV-IV) showed greatly reduced activation of NKT 
cells which was however significantly higher than that observed in mice immunized twice 
with Ova alone by the IV route (Figure 5 A). Nevertheless, ANOVA of the data for fold 
change in IFNγ production by NKT cells from mice immunized twice by the IV route with Ova 
+/- α-GalCer revealed significantly lower responses compared to that seen in mice subjected 
to one IV immunization (Figure 5 A). Also, the NKT cells from mice immunized twice with 
Ova +/- α-GalCer by the IV route did not show any differences in the expression of CD69 
while PD-1 levels remained elevated above control values, indicating anergy of NKT cells 
(Figure 5 B,C). Similarly there was a lack of DC activation subsequent to the second 
intravenous administration of α-GalCer (Figure 5 D). Furthermore, the numbers of Ova 
peptide-specific IFNγ-producing cells were higher but did not reach significance in mice 
immunized with α-GalCer+Ova as compared to those in the control group that received Ova 
alone (Figure 5 E). These results are consistent with reports from our group and those of 
others in the literature, suggesting that NKT cells were anergic in mice following the IV-IV 
regimen of immunization which may have adversely affected the development of adaptive 
immune responses. Similar results were obtained after a second dose of Ova +/- α-GalCer 
was delivered by the intranasal route to mice that received the first dose by the intravenous 
route (IV-IN regimen), after which NKT cells showed a lack of IFNγ production, a significant 
decrease in CD69, but increased PD-1 expression as compared to control mice that 
received Ova alone (Figure 5 A,B,C), all indicative of NKT cell anergy. However, the IV-IN 
regimen of immunization resulted in a statistically significant adaptive immune response as 
measured by Elispot assay (Figure 5 E) coinciding with significant activation of dendritic 
cells relative to the respective responses in mice that received only Ova protein by the IV-IN 
regimen (Figure 5 D). One possibility is that intranasal immunization targets presentation of 
α-GalCer and/or the Ova antigen to a different subset(s) of antigen presenting cells, 
sufficiently changing the interaction of APCs with NKT cells to avoid overstimulation and 
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anergy induction.  Overall, these data show that a second immunization either by the IV or 
IN route subsequent to primary IV immunization equally and significantly reduced IFNγ 
production by the NKT cells relative to that after the first IV immunization (Figure 6 A). This 
data also coincided with that from the analysis of DCs where a single IV immunization 
resulted in significantly more activated DCs than those in mice immunized either twice by 
the IV route or first by IV followed by IN, and also there was no significant difference in DC 
activation when comparing the two routes for the second immunization (Figure 6 D). This 
trend also applied to data from the analysis of PD-1 expression on the NKT cells (Figure 6 
B). However, while a single IV immunization of α-GalCer+Ova led to significantly higher 
CD69 expression by NKT cells as compared to that in mice immunized following the IV-IV 
regimen, IV-IV mice continued to express significantly more CD69 than mice following the 
IV-IN regimen, reflecting that delivery of α-GalCer by the IV route activated NKT cells more 
strongly than via the IN route (Figure 6 C).   
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Figure 5. Activation of NKT cells and DCs, and induction of antigen-specific immune 
responses in the spleen after immunization employing α-GalCer as an adjuvant. Mice 
were immunized once by the IV or twice by a combination of IV and IN routes at five day 
intervals with either Ova alone or admixed with α-GalCer (aGC+Ova). Separate groups of 
mice were sacrificed one day after each dose (days 1 and 6) for determining activation of 
NKT cells by flow cytometry (panels A-D) and at six days after each dose (day 6 and 12) for 
determining antigen-specific T cell responses by IFNγ-Elispot assay (panel E). NKT cells 
and DCs were stained as in Figure 4. Flow cytometry analyses of IFNγ production (A), 
expression of PD-1 (B) and CD69 (C) by NKT cells and CD86 expression by DC (D) of 
spleen cells from mice immunized with Ova with or without α-GalCer (Ova alone or 
aGC+Ova, respectively) are shown. Numbers of IFNγ producing cells from spleen in 
response to in vitro stimulation with the CD8 T cell epitope Ova peptide are shown as spot 
forming colonies (SFC) per 2x105 plated cells. Data are presented as mean and standard 
deviation of values collected for three mice and significance was calculated using the 
student t-test with significance at p-values ≤ 0.05(*).   
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Figure 5. Activation of NKT cells and DCs, and induction of antigen-specific immune 
responses in the spleen after immunization employing α-GalCer as an adjuvant. 
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Figure 6. Combinatorial route effect on NKT cell and DC activation in the spleen after 
immunization employing α-GalCer as an adjuvant.  Fold change in values (Mean + SD) 
for activation of NKT cells (in terms of IFNγ production as well as expression of PD-1 and 
CD69 in panels A-C), and DCs (in terms of CD86 expression in panel D) between mice 
immunized with Ova alone or with Ova+α-GalCer. Data were subjected to two-way repeated 
measure analysis of variance (ANOVA) to determine significance of effective activation 
between immunization regimens, indicated by p-values ≤ 0.05(*).   
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Figure 6. Combinatorial route effect on NKT cell and DC activation in the spleen after 
immunization employing α-GalCer as an adjuvant.  
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4.1.2 Analyses of cells from the liver 
 
The first intravenous immunization of α-GalCer+Ova, relative to immunization with 
Ova alone, induced significantly higher production of IFNγ and expression of PD-1 and 
CD69 activation markers by the NKT cells in the liver (Figure 7 A,B,C). This relative increase 
in NKT cell activation coincided with activation of DCs as measured by CD86 expression 
(Figure 7 D). Interestingly, positive adaptive response, in terms of significantly higher 
number of IFNγ-producing Ova peptide-specific CD8+ T cells relative to the assay 
background value, was observed not only in mice immunized with α-GalCer+Ova but also, 
to similar extent, in those immunized with Ova alone (Figure 7 E). Subsequent to the second 
intravenous immunization, the NKT cells in the liver exhibited functional and phenotypic 
characteristics of anergy of NKT cells in terms of lack of significant IFNγ production along 
with significantly decreased CD69 expression and significantly higher levels of PD-1, all 
relative to the values for mice immunized with Ova alone (Figure 7 A-C). Additionally, 
comparable levels of CD86 expression between mice immunized with Ova +/- α-GalCer 
indicated a lack of DC activation (Figure 7 D). These results also coincided with an adaptive 
immune response that, however, was not significantly higher than that observed in mice 
immunized twice with Ova alone (Figure 7 E). Similar results were obtained after the second 
dose of α-GalCer+Ova was delivered by the intranasal route, where NKT cells exhibited an 
anergic phenotype (Figure 7 A-C), DCs were not activated (Figure 7 D), and the adaptive 
immune response, despite being strong, was not significant relative to that in mice receiving 
Ova alone (Figure 7 E). Overall, IFNγ production as well as expression of CD69 and PD-1 
markers by the NKT cells in the liver was significantly reduced after a second dose 
regardless of the route of immunization, and also there was no difference in these 
parameters in mice immunized by the IV-IV or IV-IN regimens (Figure 8 A-C). Similar results 
were observed for the activation of DC in the liver (Figure 8 D).These data suggest that the 
intranasal administration of α-GalCer is not able to reverse the anergy of NKT cells induced 
by the prior intravenous dosing, which was reflected by a lack of significant enhancement of 
adaptive immune response by additional immunization, regardless of the route. 
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Figure 7. Activation of NKT cells and DCs, and induction of antigen-specific immune 
responses in the liver after immunization employing α-GalCer as an adjuvant. Mice 
were immunized once by the IV or twice by a combination of IV and IN routes at five day 
intervals with either Ova alone or admixed with α-GalCer (aGC+Ova). Separate groups of 
mice were sacrificed one day after each dose (days 1 and 6) for determining activation of 
NKT cells by flow cytometry (panels A-D) and at six days after each dose (day 6 and 12) for 
determining antigen-specific T cell responses by IFNγ-Elispot assay (panel E). NKT cells 
and DCs were stained as in Figure 4. Flow cytometry analyses of IFNγ production (A), 
expression of PD-1 (B) and CD69 (C) by NKT cells and CD86 expression by DC (D) of liver 
cells from mice immunized with Ova with or without α-GalCer (Ova alone or aGC+Ova, 
respectively) are shown. Numbers of IFNγ producing cells from liver in response to in vitro 
stimulation with the CD8 T cell epitope Ova peptide are shown as spot forming colonies 
(SFC) per 2x105 plated cells. Data are presented as mean and standard deviation of values 
collected for three mice and significance was calculated using the student t-test with 
significance at p-values ≤ 0.05(*).   
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Figure 7. Activation of NKT cells and DCs, and induction of antigen-specific immune 
responses in the liver after immunization employing α-GalCer as an adjuvant. 
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Figure 8. Combinatorial route effect on NKT cell and DC activation in the liver after 
immunization employing α-GalCer as an adjuvant. Fold change in values (Mean + SD) 
for activation of NKT cells (in terms of IFNγ production as well as expression of PD-1 and 
CD69 in panels A-C), and DCs (in terms of CD86 expression in panel D) between mice 
immunized with Ova alone or with Ova+α-GalCer. Data were subjected to two-way repeated 
measure analysis of variance (ANOVA) to determine significance of effective activation 
between immunization regimens, indicated by p-values ≤ 0.05(*).   
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Figure 8. Combinatorial route effect on NKT cell and DC activation in the liver after 
immunization employing α-GalCer as an adjuvant. 
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4.1.3 Analyses of cells from the lung 
 
While the lung is not considered to be a responding tissue to systemic immunization 
routes, it is the main responding tissue to intranasal immunization.(4) After an initial 
intravenous immunization with α-GalCer+Ova, the NKT cells in the lung exhibited 
characteristics of functional activation in terms of producing significant levels of IFNγ as well 
as expressing PD-1 and CD69 activation markers (Figure 9 A-C). We also observed that the 
dendritic cells were activated as evidenced by the expression of significant levels of CD86 
relative to cells from the lungs of mice that received Ova alone (Figure 9 D). Additionally, we 
observed a modest adaptive immune response, as measured by the Elispot analysis, which, 
however, did not reach significance when compared to that in mice immunized with Ova 
alone (Figure 9 E). Upon secondary immunization by the intravenous route, IFNγ production 
and CD69 expression by the NKT cells were reduced (Figure 9 A, C). However, the PD-1 
expression on the NKT cells was persistent and also significant in mice immunized with α-
GalCer+Ova relative to mice immunized with Ova alone by the IV-IV regimen (Figure 9 B). 
Despite the apparent lack of significant functional activation of NKT cells in the lung in terms 
of IFNγ production after two successive immunizations by the IV route, the DCs were 
significantly activated as measured by the CD86 expression in mice administered a second 
intravenous dose of α-GalCer+Ova relative to those immunized with Ova alone (Figure 9 D), 
though the differential increase was less dramatic and greatly reduced compared to that 
after the first IV immunization. The presence of significant DC activation corresponded to a 
significant and also improved adaptive response to the second IV immunization of α-
GalCer+Ova in this tissue, seemingly unrelated to the lack of significant IFNγ production by 
the NKT cells (Figure 9 E). A secondary intranasal immunization with α-GalCer+Ova, 
relative to Ova alone, elicited significant IFNγ production by the NKT cells while also 
exhibiting significant PD-1 expression (Figure 9 A,B) but no differential levels of CD69 
expression, unlike in the similar secondary IV immunization (Figure 9 C). The level of CD86 
expression by dendritic cells after IV-IN immunization was higher but did not reach statistical 
significance in mice immunized with α-GalCer+Ova compared to that in mice immunized 
with Ova alone (Figure 9 D), but the fold change above Ova alone control was significantly 
higher than that observed after the first IV immunization (Figure 10 D). Interestingly, 
coinciding with significant levels of IFNγ production by NKT cells, there was a significantly 
positive adaptive immune response in the lung to the secondary intranasal immunization of 
α-GalCer+Ova relative to Ova alone (Figure 9 E), and this differential response was higher 
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than that elicited by a single intravenous immunization. Overall, the initial immunization by 
the IV route with α-GalCer+Ova relative to Ova alone showed a significantly higher fold 
change in the levels of IFNγ production by the NKT cells in the lung, and a secondary 
immunization by the IV route dampened this response while a secondary IN immunization 
sustained it (Figure 10 A). It is noteworthy that despite sustained or increased IFNγ 
production by NKT cells after the second immunization by the IV or IN routes, the CD69 
expression was significantly reduced while the PD-1 levels were persistent and significantly 
higher than those observed after a single IV immunization (Figure 10 C, B). This, however, 
did not correspond to the activation of DCs, in which a single IV immunization activated DCs 
significantly more than after the second immunization by either route, and levels of 
activation for DCs in mice from IV-IV and IV-IN regimens were comparable (Figure 10 D). 
Thus, a potential link between NKT cell activation and induction of adaptive immune 
responses appears to be less consistent in this tissue, with dendritic cell activation not 
necessarily corresponding with induction of adaptive immunity.  
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Figure 9. Activation of NKT cells and DCs, and induction of antigen-specific immune 
responses in the lung after immunization employing α-GalCer as an adjuvant. Mice 
were immunized once by the IV or twice by a combination of IV and IN routes at five day 
intervals with either Ova alone or admixed with α-GalCer (aGC+Ova). Separate groups of 
mice were sacrificed one day after each dose (days 1 and 6) for determining activation of 
NKT cells by flow cytometry (panels A-D) and at six days after each dose (day 6 and 12) for 
determining antigen-specific T cell responses by IFNγ-Elispot assay (panel E). NKT cells 
and DCs were stained as in Figure 4. Flow cytometry analyses of IFNγ production (A), 
expression of PD-1 (B) and CD69 (C) by NKT cells and CD86 expression by DC (D) of lung 
cells from mice immunized with Ova with or without α-GalCer (Ova alone or aGC+Ova, 
respectively) are shown. Numbers of IFNγ producing cells from lung in response to in vitro 
stimulation with the CD8 T cell epitope Ova peptide are shown as spot forming colonies 
(SFC) per 2x105 plated cells. Data are presented as mean and standard deviation of values 
collected for three mice and significance was calculated using the student t-test with 
significance at p-values ≤ 0.05(*).   
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Figure 9. Activation of NKT cells and DCs, and induction of antigen-specific immune 
responses in the lung after immunization employing α-GalCer as an adjuvant. 
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Figure 10. Combinatorial route effect on NKT cell and DC activation in the lung after 
immunization employing α-GalCer as an adjuvant. Fold change in values (Mean + SD) 
for activation of NKT cells (in terms of IFNγ production as well as expression of PD-1 and 
CD69 in panels A-C), and DCs (in terms of CD86 expression in panel D) between mice 
immunized with Ova alone or with OVA+α-GalCer. Data were subjected to two-way 
repeated measure analysis of variance (ANOVA) to determine significance of effectivene 
activation between immunization regimens, indicated by p-values ≤ 0.05(*).   
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Figure 10. Combinatorial route effect on NKT cell and DC activation in the lung after 
immunization employing α-GalCer as an adjuvant. 
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4.1.4 Analyses of cells from the mediastinal lymph nodes (MdLN) 
 
Finally, we analyzed cells isolated from the lung-draining mediastinal lymph nodes of 
mice immunized with Ova+/-α-GalCer first by the IV route and followed in separate groups 
by a second immunization by either the IV or IN route. After the first IV immunization with α-
GalCer+Ova, relative to Ova alone, the NKT cells produced a higher amount of IFNγ but 
showed no difference in the expression of either PD-1 or CD69, suggesting poor activation 
(Figure 11 A-C). Correspondingly, there was minimal activation of DC which was not 
significantly different from what was detected in mice immunized with Ova alone, and also 
no adaptive immune response was observed (Figure 11 D). These results suggest that the 
observed IFNγ+ NKT cells may not be those which are resident in the MdLN and/or possibly 
drained to this tissue from the lung, a tissue in which NKT cells produced significant 
amounts of IFNγ (Figure 9 A). A second immunization with α-GalCer+Ova by the IV route 
did not result in reactivation of NKT cells in terms of IFNγ production or CD69 expression, 
but PD-1 levels were significantly higher than those in mice immunized with Ova alone 
(Figure 11 A,C,B). Even though the second IV immunization with α-GalCer+Ova resulted in 
significant DC activation relative to that in mice immunized  with Ova alone, the overall level 
of DC activation in the mice from the IV-IV immunization regimen was lower than what was 
observed after the first IV immunization with α-GalCer+Ova (Figure 11 D). However, this low 
but significant level of DC activation in mice immunized with α-GalCer+Ova, relative to mice 
immunized with Ova alone, did not translate to a positive adaptive immune response (Figure 
11 E). As speculated above, it is possible that the activated dendritic cells observed in the 
MdLN were a result of migration from another tissue. In response to a secondary intranasal 
immunization with α-GalCer+Ova, once again there was no activation of NKT cells as 
measured by a lack of IFNγ production, significantly higher expression of PD-1, and 
significantly decreased  CD69 expression as well as no DC activation when compared to 
mice immunized with Ova alone (Figure 11 A-D). Despite the lack of functional activation of 
NKT cells and DC in mice from the IV-IN regimen, there was a significantly positive adaptive 
immune response in this tissue relative to that in mice administered Ova alone (Figure 11 
E), which might also be a result of migration of antigen-specific CD8+ T cells from the lung. 
Overall, ANOVA of data from mice immunized with Ova +/- α-GalCer once or twice by the IV 
route (IV and IV-IV regimens respectively) or first by the IV route followed by the IN route 
(IV-IN regimen) showed no significant difference in regards to IFNγ production as well as 
PD-1 expression by the NKT cells in the MdLN (Figure 12 A-B). However, with respect to 
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CD69 expression by the NKT cells, significantly higher levels were observed in mice that 
received a single IV immunization when compared to those in mice that followed the IV-IN 
regimen, while mice following the IV-IV regimen showed levels that were comparable to 
those in mice administered a single IV immunization (Figure 12 C). Also, CD69 expression 
was comparable between the IV-IV and IV-IN groups of mice (Figure 12 C). Finally, the 
ANOVA for these data revealed that activation of DCs was significantly higher in mice from 
the single IV regimen than those in both the IV-IV and IV-IN regimens, while the data for the 
mice in the IV-IV and IV-IN regimens were comparable (Figure 12 D).Thus, it appears that in 
this tissue, activation of DCs may be a result of migration from another tissue, as all other 
factors are negative for activation.  
Overall, in the liver, a tissue generally considered to be mainly responsive to IV 
immunization, it appears that a single IV dose of α-GalCer strongly activates NKT cells 
leading to an anergic phenotype in those cells. Subsequent dosing, regardless of route, was 
not able to overcome this anergy. However, in the lung, a tissue that may not be considered 
a main responder to systemic immunization, it appears that activation of NKT cells as 
measured by IFNγ production in these tissues is able only to induce a minimal adaptive 
immune response. While subsequent IV dosing does not elicit response in these tissues, it 
appears that the resident NKT cells remain responsive to intranasal immunization.  
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Figure 11. Activation of NKT cells and DCs, and induction of antigen-specific immune 
responses in the MdLN after immunization employing α-GalCer as an adjuvant. Mice 
were immunized once by the IV or twice by a combination of IV and IN routes at five day 
intervals with either Ova alone or admixed with α-GalCer (aGC+Ova). Separate groups of 
mice were sacrificed one day after each dose (days 1 and 6) for determining activation of 
NKT cells by flow cytometry (panels A-D) and at six days after each dose (day 6 and 12) for 
determining antigen-specific T cell responses by IFNγ-Elispot assay (panel E). NKT cells 
and DCs were stained as in Figure 4. Flow cytometry analyses of IFNγ production (A), 
expression of PD-1 (B) and CD69 (C) by NKT cells and CD86 expression by DC (D) of 
MdLN cells from mice immunized with Ova with or without α-GalCer (Ova alone or 
aGC+Ova, respectively) are shown. Numbers of IFNγ producing cells from MdLN in 
response to in vitro stimulation with the CD8 T cell epitope Ova peptide are shown as spot 
forming colonies (SFC) per 2x105 plated cells. Data are presented as mean and standard 
deviation of values collected for three mice and significance was calculated using the 
student t-test with significance at p-values ≤ 0.05(*).   
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Figure 11. Activation of NKT cells and DCs, and induction of antigen-specific immune 
responses in the MdLN after immunization employing α-GalCer as an adjuvant. 
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Figure 12. Combinatorial route effect on NKT cell and DC activation in the MdLN after 
immunization employing α-GalCer as an adjuvant. Fold change in values (Mean + SD) 
for activation of NKT cells (in terms of IFNγ production as well as expression of PD-1 and 
CD69 in panels A-C), and DCs (in terms of CD86 expression in panel D) between mice 
immunized with Ova alone or with Ova+α-GalCer. Data were subjected to two-way repeated 
measure analysis of variance (ANOVA) to determine significance of effective activation 
between immunization regimens, indicated by p-values ≤ 0.05(*).   
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Figure 12. Combinatorial route effect on NKT cell and DC activation in the MdLN after 
immunization employing α-GalCer as an adjuvant.
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 4.2 EFFECT OF A-GALCER WHEN DELIVERED VIA THE IN
 
We next investigated the effects of a priming intranasal immunization of Ova+/
GalCer followed by a boosting dose delivered by the intravenous versus intranasal route 
(Figure 13) on the activation of NKT cells and DCs and induction of adaptive immunity to the 
Ova antigen. All results for these experiments were presented as a comparison of 
responses in mice immunized with 
alone.  
Figure 13. IN-IN/IV-IN immunization scheme.
Figure 13. Mice were immunized with Ova+/
by second immunization either by the intravenous or intranasal route at day 5 after the 
primary immunization. Both IN
Mice were sacrificed on days 1, 6, 11 and 15 post
 
4.2.1 Analyses of cells from the spleen
 
After the first immunization with 
activated NKT cells in terms of production of IFN
but DC activation was not significantly different from control mice that were administered 
Ova alone (Figure 14 A-D). However, we observed a significant amount of adaptive 
response as measured by the IFN
immunization with α-GalCer+Ova reactivated NKT cells to produce significant amounts of 
IFNγ along with significant expression of PD
activation of DCs in terms of CD86 expression, while higher in mice administered 
GalCer+Ova than those receiving Ova alone, did not reach significance, and 
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correspondingly adaptive immune response was higher but was not significantly different 
from control value in mice immunized with Ova alone (Figure 14 D-E). A second 
immunization with α-GalCer+Ova delivered by the IV route to mice that initially were 
immunized by the IN route resulted in significant activation of NKT cells in terms of IFNγ 
production as well as expression of PD-1 and CD69, with corresponding significant DC 
activation and a positive adaptive immune response, which was higher than control values 
from mice immunized with Ova alone but did not reach statistical significance (Figure 14 A-
E). Sequential immunizations with α-GalCer+Ova, relative to Ova alone, first by the IN route 
followed by IV route (IN-IV) resulted in slightly higher levels of IFNγ-producing NKT cells 
when compared to that after the first IN immunization (Figure 15 A). However, two 
sequential immunization by the IN route (IN-IN) with α-GalCer+Ova, relative to Ova alone, 
resulted in NKT cells producing significantly lower levels of IFNγ than those in mice that 
followed the IN or IN-IV immunization regimen (Figure 15 A). Similar ANOVA of the PD-1 
expression by the NKT cells showed comparable levels between IN and IN-IV groups, but 
significant reduction when values for mice in the IN-IN group were compared to those for 
mice in the IN and IN-IV groups (Figure 15 B). The CD69 expression is significantly elevated 
in mice immunized by the IN-IV and also the IN-IN groups relative to mice immunized once 
by the IN route. We also observed that CD69 expression in mice from the IN-IV group was 
significantly higher than that in mice from the IN-IN group (Figure 15 C). With respect to DC 
activation, immunization by the IN-IN as well as IN-IV regimens resulted in significantly 
elevated CD86 expression above one dose, while the DC activation after IN-IV immunization 
was significantly elevated above that after IN-IN immunization (Figure 15 D). Finally, a third 
consecutive dose of α-GalCer delivered by the IN route (IN-IN-IN scheme) showed 
reactivation of NKT cells to produce IFNγ, along with significant expression of PD-1and 
CD69 activation markers (Figure 14 A-C). The DC activation in mice immunized with α-
GalCer+Ova by the IN-IN-IN regimen was minimal but significantly increased above that in 
mice administered Ova alone, and the adaptive response was also similarly higher but did 
not reach significance (Figure 14 D-E). A third immunization with α-GalCer+Ova by the IN 
route to mice that previously received two successive immunizations by the IN-IV regimen 
(IN-IV-IN scheme) also reactivated NKT cells to produce IFNγ, although the levels were 
reduced as compared to mice that did not receive a third IN immunization (IN-IV regimen) 
(Figure 14 A). The level of PD-1 expression on the NKT cells in mice from the IN-IV-IN 
immunization scheme was significant, but CD69 expression was not, and also no significant 
DC activation was observed (Figure 14 B-D). However, in the mice immunized with α-
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GalCer+Ova by the IN-IV-IN regimen, the adaptive immune response as measured by the 
IFNγ Elispot assay indicated a significant increase above that in control mice immunized 
with Ova alone (Figure 14 E). Overall, the level of IFNγ production by NKT cells was not 
significantly changed by a third immunization following the IN-IV or IN-IN regimens, making 
each three dose scheme comparable (Figure 15 A). Immunization by the IN-IV regimen 
followed by a third IN immunization resulted in significant up-regulation of PD-1 expression 
on NKT cells in the spleen, and similar results were obtained from mice that received a third 
IN immunization (IN-IN-IN) (Figure 15 B). However, PD-1 levels in mice from the IN-IV-IN 
immunization scheme were significantly higher than those in mice from the IN-IN-IN scheme 
(Figure 15 B). Similarly, a third IN immunization following the IN-IV scheme (IN-IV-IN) 
resulted in a significant drop in CD69 expression which was not the case with the IN-IN-IN 
scheme that remained comparable to the values observed in mice from the IN-IN scheme, 
making CD69 expression on NKT cells in mice from the IN-IV-IN group significantly less 
than that from mice in the IN-IN-IN group (Figure 15 C). The level of DC activation in terms 
of CD86 expression in mice following the IN-IV-IN regimen was significantly reduced 
compared to that in mice following the IN-IV regimen (Figure 15 D). However, CD86 
expression on DC induced by IN-IN-IN immunization was comparable to that observed for 
mice in the IN-IN as well as IN-IV-IN groups (Figure 15 D). These results suggest that 
repeated activation of NKT cells occurs after multiple rounds of intranasal immunization in 
the spleen, but this does not correspond strictly to the induction of positive adaptive immune 
responses, which appear to be more dependent on the activation status of the antigen 
presenting DCs.  
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Figure 14. Activation of NKT cells and DCs, and induction of antigen-specific immune 
responses in the spleen after immunization employing α-GalCer as an adjuvant. Mice 
were immunized once by the IV or twice by a combination of IV and IN routes at five day 
intervals with either Ova alone or admixed with α-GalCer (aGC+Ova). Separate groups of 
mice were sacrificed one day after each dose (days 1, 6, and 11) for determining activation 
of NKT cells by flow cytometry (panels A-D) and at 5-6 days after each dose (day 6, 11, 15) 
for determining antigen-specific T cell responses by IFNγ-Elispot assay (panel E). NKT cells 
and DCs were stained as in Figure 4. Flow cytometry analyses of IFNγ production (A), 
expression of PD-1 (B) and CD69 (C) by NKT cells and CD86 expression by DC (D) of 
spleen cells from mice immunized with Ova with or without α-GalCer (Ova alone or 
aGC+Ova, respectively) are shown. Numbers of IFNγ producing cells from spleen in 
response to in vitro stimulation with the CD8 T cell epitope Ova peptide are shown as spot 
forming colonies (SFC) per 2x105 plated cells. Data are presented as mean and standard 
deviation of values collected for three mice and significance was calculated using the 
student t-test with significance at p-values ≤ 0.05(*).   
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Figure 14. Activation of NKT cells and DCs, and induction of antigen-specific immune 
responses in the spleen after immunization employing α-GalCer as an adjuvant. 
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Figure 15. Combinatorial route effect on NKT cell and DC activation in the MdLN after 
immunization employing α-GalCer as an adjuvant. Fold change in values (Mean + SD) 
for activation of NKT cells (in terms of IFNγ production as well as expression of PD-1 and 
CD69 in panels A-C), and DCs (in terms of CD86 expression in panel D) between mice 
immunized with Ova alone or with Ova+α-GalCer. Data were subjected to two-way repeated 
measure analysis of variance (ANOVA) to determine significance of effective activation 
between immunization regimens, indicated by p-values ≤ 0.05(*).   
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Figure 15. Combinatorial route effect on NKT cell and DC activation in the spleen after 
immunization employing α-GalCer as an adjuvant.  
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4.2.2 Analyses of cells from the liver 
 
An initial intranasal dose of α-GalCer+Ova, relative to Ova alone, induced stronger 
activation of NKT cells in the liver in terms of significant levels of IFNγ production and CD69 
expression but no difference in the level of PD-1 expression (Figure 16 A,C,B). In parallel, 
we observed significant activation of DCs in terms of CD86 expression and a strong 
adaptive immune response (Figure 16 D-E). A second dose of α-GalCer+Ova delivered by 
the intranasal route (IN-IN regimen) resulted in negligible IFNγ production by NKT cells and 
no difference in the expression of PD-1 or CD69 in comparison to mice the received Ova 
alone (Figure 16 A-C). Although not significantly activated, DCs in the liver showed levels of 
CD86 expression comparable to those after the first intranasal dose, and adaptive immune 
responses in the liver remained at a level significantly higher than that in mice immunized 
with Ova alone (Figure 16 D-E). Analyses of cells from mice administered a second 
intravenous immunization subsequent to the first immunization by the intranasal route (IN-IV 
regimen) also showed reactivation of NKT cells to produce IFNγ, in addition to expression of 
significant amounts of PD-1 (Figure 16 A-B). While high levels of CD69 expression were 
observed in the mice receiving repeat doses of α-GalCer+Ova following the IN-IV regimen, 
they were comparable to those in mice in the control group immunized with Ova alone 
(Figure 16 C). Furthermore, DCs were significantly activated in mice administered two doses 
of α-GalCer+Ova, relative to Ova alone, following the IN-IV regimen, which coincided with 
positive adaptive immune response (Figure 16 D-E). ANOVA of data from the liver cells of 
mice that received a single IN immunization showed significantly more IFNγ production by 
NKT cells than that in mice administered a second dose by either the IN or IV route (IN-IN 
and IN-IV regimens, respectively) and that a second IV dose (IN-IV regimen) resulted in 
significantly higher IFNγ production by NKT cells than that observed after a second IN dose 
(IN-IN regimen) (Figure 17 A). The PD-1 levels on NKT cells in mice administered a single 
IN dose were comparable to those in mice from the IN-IV regimen, but PD-1 levels on NKT 
cells in mice following the IN-IN regimen were significantly less than in mice that were 
immunized either once by the IN route or after IN-IV immunization (Figure 17 B). With 
respect to the CD69 expression on NKT cells, the levels in mice from both IN-IV and IN-IN 
regimens were significantly higher than in mice that received a single IN immunization 
(Figure 17 C). Also, mice following the IN-IV regimen showed significantly more CD69 
expression than those following the IN-IN regimen. Finally, DCs in the livers of mice from the 
IN-IN group expressed CD86 levels comparable to those in mice administered a single IN 
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immunization, but a second IV immunization (IN-IV regimen) following the initial IN 
immunization led to significantly more CD86 expression on DC (Figure 17 D). Nevertheless, 
the DC activation levels, in terms of CD86 expression, were comparable in mice from both 
the IN-IV and IN-IN regimen groups. Since a single dose of α-GalCer delivered by the 
intravenous route induces anergy of NKT cells (as shown in the current study as well as in 
literature reports), we investigated whether or not the second intravenous dose of α-GalCer 
delivered to mice that originally received an initial intranasal dose of α-GalCer would also 
result in anergy of the NKT cells. We therefore administered a third intranasal immunization 
of α-GalCer +/- Ova to mice from the IN-IN and IN-IV regimen groups. Cells from the livers 
of mice administered α-GalCer+Ova, relative to Ova alone, by the IN-IN-IN regimen did not 
show induction of significant IFNγ production by NKT cells (Figure 16 A). Correspondingly, 
expression levels of both CD69 and PD-1 were similar to that in the control group of mice 
receiving Ova alone by the IN-IN-IN regimen (Figure 16 B-C). However, levels of DC 
activation remained significant, and this coincided with a positive adaptive immune response 
in mice immunized with α-GalCer+Ova relative to Ova alone control by the IN-IN-IN regimen 
(Figure 16 D-E). In the case of the mice following the IN-IV-IN immunization scheme, 
subsequent to the third dose, the NKT cells did not show IFNγ production, but PD-1 
expression was significant, suggesting anergy (Figure 16 A-B). Additionally, CD69 
expression was significantly down-regulated compared to Ova alone control, and DCs were 
also not significantly activated (Figure 16 C-D). Adaptive immune response after the IN-IV-
IN immunization regimen remained comparable to that observed in mice receiving two 
immunizations by the IN-IV regimen, but was not significantly different than those in mice 
that received Ova alone by the IN-IV-IN scheme (Figure 16 E). In summary, a third 
intranasal immunization to mice that were earlier immunized by the IN-IV scheme resulted in 
significantly less IFNγ production by NKT cells than after IN-IV dosing, whereas a third 
intranasal immunization subsequent to IN-IN immunization resulted in comparable IFNγ 
production by NKT cells to that after two successive IN immunizations (IN-IN regimen) 
(Figure 17 A). Also, mice immunized using the IN-IV-IN scheme showed NKT cells 
producing significantly less IFNγ than those from mice following the IN-IN-IN regimen. The 
PD-1 expression levels in mice following the IN-IV and IN-IV-IN schemes were comparable, 
but the IN-IN-IN immunization scheme resulted in significantly more PD-1 expression on 
NKT cells than in mice following the IN-IN scheme (Figure 17 B). Overall, three 
immunizations, regardless of the route used for the second dose, resulted in comparable 
expression of PD-1 by NKT cells. Following the IN-IV scheme of immunization with a third 
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dose resulted in significantly less CD69 expression, but the levels for mice in the IN-IN and 
IN-IN-IN groups were comparable (Figure 17 C). Also, NKT cells in the livers of mice 
following the IN-IV-IN and IN-IN-IN schemes showed CD69 expression that were 
significantly different from one another. Lastly, CD86 expression on DCs after a third 
immunization  was significantly reduced as compared to that in mice receiving IN-IV 
immunization, but was similar to CD86 levels on DCs in mice following the IN-IN regimen 
(Figure 17 D). Thus, the IN-IN-IN immunization regimen resulted in significantly higher CD86 
expression on DC than the IN-IV-IN regimen. In the liver tissue, an initial dose of α-GalCer 
delivered by the IN route followed by a second IV dose seemed to have induced anergy in 
NKT cells as indicated by high expression of PD-1, but did not blunt the adaptive immune 
response which was the case after two successive doses of α-GalCer delivered by the IV 
route.  Multiple doses of α-GalCer delivered by the IN route did not induce reactivation of 
NKT cells in the liver, but significant DC activation and positive adaptive immune responses 
were observed after each dose, suggesting that perhaps activated DCs are homing to the 
liver from elsewhere and influencing the induction of adaptive immune response in this 
tissue. 
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Figure 16. Activation of NKT cells and DCs, and induction of antigen-specific immune 
responses in the liver after immunization employing α-GalCer as an adjuvant. Mice 
were immunized once by the IV or twice by a combination of IV and IN routes at five day 
intervals with either Ova alone or admixed with α-GalCer (aGC+Ova). Separate groups of 
mice were sacrificed one day after each dose (days 1, 6, and 11) for determining activation 
of NKT cells by flow cytometry (panels A-D) and at 5-6 days after each dose (day 6, 11, 15) 
for determining antigen-specific T cell responses by IFNγ-Elispot assay (panel E). NKT cells 
and DCs were stained as in Figure 4. Flow cytometry analyses of IFNγ production (A), 
expression of PD-1 (B) and CD69 (C) by NKT cells and CD86 expression by DC (D) of liver 
cells from mice immunized with Ova with or without α-GalCer (Ova alone or aGC+Ova, 
respectively) are shown. Numbers of IFNγ producing cells from liver in response to in vitro 
stimulation with the CD8 T cell epitope Ova peptide are shown as spot forming colonies 
(SFC) per 2x105 plated cells. Data are presented as mean and standard deviation of values 
collected for three mice and significance was calculated using the student t-test with 
significance at p-values ≤ 0.05(*).   
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Figure 16. Activation of NKT cells and DCs, and induction of antigen-specific immune 
responses in the liver after immunization employing α-GalCer as an adjuvant. 
  
IN
IN
-IN
IN
-IN
-IN
IN
-IV
IN
-IV
-IN
 
  
  
67 
 
Figure 17. Combinatorial route effect on NKT cell and DC activation in the liver after 
immunization employing α-GalCer as an adjuvant. Fold change in values (Mean + SD) 
for activation of NKT cells (in terms of IFNγ production as well as expression of PD-1 and 
CD69 in panels A-C), and DCs (in terms of CD86 expression in panel D) between mice 
immunized with Ova alone or with Ova+α-GalCer. Data were subjected to two-way repeated 
measure analysis of variance (ANOVA) to determine significance of effective activation 
between immunization regimens, indicated by p-values ≤ 0.05(*). 
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Figure 17. Combinatorial route effect on NKT cell and DC activation in the liver after 
immunization employing α-GalCer as an adjuvant. 
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4.2.3 Analyses of cells from the lung 
 
One immunization by the IN route with α-GalCer+Ova induced strong activation of 
NKT cells in the lung leading to significant IFNγ production as well as expression of PD-1 
and CD69 relative to that observed in the control group of mice immunized with Ova alone 
(Figure 18 A-C). We also observed DCs in this tissue were significantly activated after the IN 
immunization, and correspondingly a positive adaptive immune response, in terms of Ova-
specific IFNγ-producing CD8+ T cells, was observed (Figure 18 D-E). Administration of the 
second IN immunization of α-GalCer+Ova led to significant IFNγ production by NKT cells, 
albeit at reduced levels as compared to those after the first immunization (Figure 18 A). The 
second intranasal immunization also induced significant expression of both CD69 and PD-
1on the NKT cells (Figure 18 B-C). We also observed significant activation of DCs and 
positive adaptive immune response after the second successive IN immunization with α-
GalCer+Ova (Figure 18 D-E). In contrast to this, a second IV dose of α-GalCer following an 
initial IN dose did not reactivate NKT cells to produce significant amounts of IFNγ, but PD-1 
levels remained significant, and CD69 was strongly and significantly up-regulated relative to 
mice immunized with Ova alone by the IN-IV regimen (Figure 18 A-C). Likewise, dendritic 
cells were activated and induction of a positive adaptive immune response was observed, 
suggesting that perhaps IFNγ production by the NKT cells might not be the sole factor 
influencing DC activation in this tissue to promote induction of adaptive immunity (Figure 18 
D-E). The levels of IFNγ production by NKT cells in response to immunization with α-
GalCer+Ova, relative to Ova alone, in mice from the IN-IN and IN-IV regimens were 
significantly less than that observed after the initial IN immunization, but the responses were 
comparable among mice immunized by the two regimens (IN-IV and IN-IN) (Figure 19 A). 
While similar comparisons for the expression of PD-1 on NKT cells in mice immunized by 
the IN-IN or IN-IV regimen were each comparable to that after the first IN immunization, 
mice following the IN-IN immunization regimen showed PD-1 expression that was 
significantly less than that observed in the IN-IV regimen mice (Figure 19 B). Furthermore, 
CD69 expression on the NKT cells was significantly higher in mice from the IN-IV 
immunization regimen as compared to that observed after both a single or two sequential 
immunizations by the IN route, with responses in the latter two groups being comparable to 
one another (Figure 19 C). Parallel analyses of the DCs in terms of CD86 expression in the 
lungs of mice immunized with α-GalCer+Ova versus Ova alone revealed significantly more 
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activation after the second immunization, whether by the IN or IV routes, and the levels of 
CD86 expression on the DCs in mice from the IN-IN and IN-IV groups were similar to one 
another (Figure 19 D). Finally, a third consecutive immunization with α-GalCer+Ova, relative 
to Ova alone, by the IN-IN-IN scheme did not induce significant IFNγ production by NKT 
cells that, however, showed significant levels of expression of PD-1 and CD69 activation 
markers (Figure 18 A-C). Likewise, DCs were activated and a positive adaptive CD8+ T cell 
immune response was observed in the mice following the IN-IN-IN immunization regimen, 
albeit not significant above background (Figure 18 D-E). These results suggest that IFNγ 
production by NKT cells subsequent to the third successive dose of α-GalCer+Ova delivered 
by the IN route may be dispensable for the activation of DCs and/or induction of adaptive 
immunity to co-administered antigen, particularly in the lung tissue. Analyses of the cells 
from the lungs of mice that received α-GalCer+Ova using the IN-IV-IN dosing scheme 
showed no activation of NKT cells in terms of IFNγ production and CD69 expression, but 
PD-1 levels were significantly higher than in the control mice that received Ova alone in this 
scheme (Figure 18 A,C,B). While the DCs were not activated in these mice, adaptive 
immune response remained significant but decreased as compared to that in mice that did 
not receive the third IN immunization (i.e. mice in the IN-IV regimen) (Figure 18 D-E). In the 
lung, the third immunization by the IN route to mice that were immunized previously by 
either the IN-IV or IN-IN regimens induced significantly more IFNγ production by NKT cells, 
supporting the effectiveness of the IN route of α-GalCer delivery to repeatedly activate NKT 
cells, regardless of the route of immunization used in the earlier second immunization 
(Figure 19 A). The difference in the PD-1 expression by NKT cells between mice following 
the IN-IV and IN-IN regimens was significant, with IN-IV inducing higher PD-1 expression 
that was not significantly different from IN-IV-IN. IN-IN-IN immunization resulted in a 
significant drop in PD-1 expression compared to two doses IN-IN (Figure 19 B). Also, mice 
in the IN-IV-IN and IN-IN-IN groups showed levels of PD-1 expression in the lung NKT cells 
that were comparable to one another. The level of CD69 expression on the NKT cells was 
significantly reduced in mice from the IN-IV-IN group as compared to that in mice from the 
IN-IV group, but was significantly increased in the mice from the IN-IN-IN group versus 
those in both the IN-IN and IN-IV-IN groups (Figure 19 C). Lastly, DCs in the lung were 
significantly more activated after immunization by the IN-IV scheme than what was observed 
in mice following the IN-IV-IN scheme, whereas two and three immunizations delivered by 
the IN route led to similar levels of DC activation (Figure 19 D). The DCs in the mice from 
the IN-IN-IN group showed CD86 expression that was significantly higher than what was 
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observed in mice from the IN-IV-IN immunization group. Overall, these results from the 
analyses of cells from the lung tissue of mice immunized with α-GalCer+Ova versus Ova 
alone by the IN-IV +/- IN regimens suggest that IFNγ production by the NKT cells in 
response to α-GalCer may not be the sole underlying mechanism for the activation of DCs 
and/or eventual induction of adaptive immune response to the co-administered antigen, but 
might be related to CD69 expression by NKT cells and, further downstream, DC activation 
status.  
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Figure 18. Activation of NKT cells and DCs, and induction of antigen-specific immune 
responses in the lung after immunization employing α-GalCer as an adjuvant. Mice 
were immunized once by the IV or twice by a combination of IV and IN routes at five day 
intervals with either Ova alone or admixed with α-GalCer (aGC+Ova). Separate groups of 
mice were sacrificed one day after each dose (days 1, 6, and 11) for determining activation 
of NKT cells by flow cytometry (panels A-D) and at 5-6 days after each dose (day 6, 11, 15) 
for determining antigen-specific T cell responses by IFNγ-Elispot assay (panel E). NKT cells 
and DCs were stained as in Figure 4. Flow cytometry analyses of IFNγ production (A), 
expression of PD-1 (B) and CD69 (C) by NKT cells and CD86 expression by DC (D) of lung 
cells from mice immunized with Ova with or without α-GalCer (Ova alone or aGC+Ova, 
respectively) are shown. Numbers of IFNγ producing cells from lung in response to in vitro 
stimulation with the CD8 T cell epitope Ova peptide are shown as spot forming colonies 
(SFC) per 2x105 plated cells. Data are presented as mean and standard deviation of values 
collected for three mice and significance was calculated using the student t-test with 
significance at p-values ≤ 0.05(*).   
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Figure 18. Activation of NKT cells and DCs, and induction of antigen-specific immune 
responses in the lung after immunization employing α-GalCer as an adjuvant. 
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Figure 19. Combinatorial route effect on NKT cell and DC activation in the lung after 
immunization employing α-GalCer as an adjuvant. Fold change in values (Mean + SD) 
for activation of NKT cells (in terms of IFNγ production as well as expression of PD-1 and 
CD69 in panels A-C), and DCs (in terms of CD86 expression in panel D) between mice 
immunized with Ova alone or with Ova+α-GalCer. Data were subjected to two-way repeated 
measure analysis of variance (ANOVA) to determine significance of effective activation 
between immunization regimens, indicated by p-values ≤ 0.05(*). 
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Figure 19. Combinatorial route effect on NKT cell and DC activation in the lung after 
immunization employing α-GalCer as an adjuvant.  
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4.2.4 Analyses of cells from the mediastinal lymph node (MdLN) 
 
An initial intranasal immunization with α-GalCer+Ova induced strong IFNγ production 
by NKT cells in the lung-draining mediastinal lymph node (MdLN), and the expression of PD-
1 and CD69 activation markers was higher than background levels (Figure 20 A-C). While 
the DCs did not exhibit strong activation, a significantly positive adaptive immune response 
was observed (Figure 20 D-E). It is possible that the Ova-specific CD8+ T cells responsible 
for the adaptive immune response drained to the MdLN from the lung or another tissue. All 
subsequent doses of α-GalCer delivered by either the IN or IV route did not induce IFNγ 
production by the NKT cells in the MdLN, and there was also a lack of significant CD69 
expression by the NKT cells (Figure 20 A,C). We also did not observe DC activation, 
although mice administered α-GalCer by the IN-IN and IN-IV schemes showed a trend for 
increased DC activation (Figure 20 D). The PD-1 expression on the NKT cells was also not 
significant following α-GalCer delivery by any route (Figure 20 B), although it was interesting 
to note that the biggest fold change in PD-1 expression between mice receiving Ova alone 
and α-GalCer+Ova was observed in the IN-IV scheme (Figure 21 B), consistent with an 
anergy phenotype of NKT cells. While mice immunized with α-GalCer+Ova, relative to Ova 
alone, by any of the regimens except IN-IN-IN showed higher adaptive immune response in 
terms of Ova-specific IFNγ-producing CD8+ T cells, the levels were significant only in mice 
that received on IN immunization and those that were immunized following the IN-IV 
regimen (Figure 20 E). Overall, it appears that the lack of adaptive response in the MdLN 
following the IN-IN-IN immunization scheme was due simply to lack of sufficient activation of 
NKT cells rather than anergy, as also indicated by a lack of significant DC activation. In 
comparing data from all immunization regimens by ANOVA of mice administered α-
GalCer+Ova versus Ova alone, the only point at which there is a significant difference in 
IFNγ production is after a single IN dose, which is significantly higher than either of the 
subsequent second immunizations (Figure 21 A). Similar analyses revealed that PD-1 
expression was significantly higher after a single IN immunization than after a second 
immunization by either the IN or IV route, and the IN-IV-IN immunization regimen induced a 
significant increase in PD-1 expression above that observed in mice that followed the IN-IV 
immunization scheme (Figure 21 B). However this level of PD-1 expression induced by IN-
IV-IN immunization was comparable to that seen in mice from the IN-IN and IN-IN-IN 
immunization regimens. A single IN immunization with α-GalCer+Ova, relative to Ova alone, 
resulted in significantly higher CD69 expression on NKT cells than that observed after either 
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of the second immunizations, and mice immunized by the IN-IV regimen showed 
significantly higher levels compared to that in mice immunized by the IN-IN regimen (Figure 
21 C). The third IN immunization following the IN-IV regimen (IN-IV-IN) resulted in a 
significant decrease in CD69 expression, but expression after a third IN immunization 
following the IN-IN regimen (IN-IN-IN) was comparable to that observed after IN-IN 
immunization. Both three dose schemes resulted in similar levels of CD69 expression on 
NKT cells. Lastly, IN immunization followed by either a second IN or IV immunization 
resulted in significantly higher CD86 expression on DC, with IN-IN and IN-IV regimens being 
comparable (Figure 21 D). A third IN dose after each of these schemes resulted in 
significant decrease in CD86 expression as compared to the relative two dose scheme, with 
both three dose schemes being comparable to one another.  
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Figure 20. Activation of NKT cells and DCs, and induction of antigen-specific immune 
responses in the MdLN after immunization employing α-GalCer as an adjuvant. Mice 
were immunized once by the IV or twice by a combination of IV and IN routes at five day 
intervals with either Ova alone or admixed with α-GalCer (aGC+Ova). Separate groups of 
mice were sacrificed one day after each dose (days 1, 6, and 11) for determining activation 
of NKT cells by flow cytometry (panels A-D) and at 5-6 days after each dose (day 6, 11, 15) 
for determining antigen-specific T cell responses by IFNγ-Elispot assay (panel E). NKT cells 
and DCs were stained as in Figure 4. Flow cytometry analyses of IFNγ production (A), 
expression of PD-1 (B) and CD69 (C) by NKT cells and CD86 expression by DC (D) of 
MdLN cells from mice immunized with Ova with or without α-GalCer  (Ova alone or 
aGC+Ova, respectively) are shown. Numbers of IFNγ producing cells from MdLN in 
response to in vitro stimulation with the CD8 T cell epitope Ova peptide are shown as spot 
forming colonies (SFC) per 2x105 plated cells. Data are presented as mean and standard 
deviation of values collected for three mice and significance was calculated using the 
student t-test with significance at p-values ≤ 0.05(*).   
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Figure 20. Activation of NKT cells and DCs, and induction of antigen-specific immune 
responses in the MdLN after immunization employing α-GalCer as an adjuvant. 
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Figure 21. Combinatorial route effect on NKT cell and DC activation in the MdLN after 
immunization employing α-GalCer as an adjuvant. Fold change in values (Mean + SD) 
for activation of NKT cells (in terms of IFNγ production as well as expression of PD-1 and 
CD69 in panels A-C), and DCs (in terms of CD86 expression in panel D) between mice 
immunized with Ova alone or with Ova+α-GalCer. Data were subjected to two-way repeated 
measure analysis of variance (ANOVA) to determine significance of effective activation 
between immunization regimens, indicated by p-values ≤ 0.05(*). 
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Figure 21. Combinatorial route effect on NKT cell and DC activation in the MdLN after 
immunization employing α-GalCer as an adjuvant.  
 
 
  
 4.3 CONSECUTIVE INTRANASAL IMMUNIZATIONS VIA THE IN
 
As described above, experiments testing combinations of immunization by the IN 
and IV routes showed that multiple immunizations, up to three doses, by the in
afforded reactivation of NKT cells along with DC activation and induction of adaptive 
immune response in the lung tissue
effectiveness of four sequential immunizations by the IN route to induce 
responses. Briefly, mice were administered four intranasal doses of 
day intervals, and separate groups of mice were sacrificed five days after each dose to 
analyze various tissues for IFN
(Figure 22). As described above, a single immunization with 
alone, induced a positive adaptive immune response in the spleen, lung and MdLN tissues 
(Figure 23). A second intranasal immunizatio
response in these tissues, with a trend of improvement in the lung and MdLN tissues, but 
decrease in the spleen. A third immunization again led to a positive adaptive response in 
these three tissues, but the levels
second IN immunizations. After the fourth and final immunization, while the response in all 
tissues was still positive, that in the lung was reduced to a level that was only slightly above 
the background cutoff value, and while it was significantly positive in the spleen, adaptive 
response in this tissue decreased relative to one, two, and three immunizations by the IN 
route. 
Figure 22. Scheme for 
sequential immunization 
four times by the intranasal 
route.  
Mice were immunized from 
one to four times (1D to 4D) at seven day intervals
Ova alone or admixed with α
after each immunization (days 5, 12, 19, and 26 post
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Figure 23. Induction of Ova peptide-specific IFNγ-producing cells by four consecutive 
intranasal immunizations with the Ova +/- α-GalCer as adjuvant.  
Cells isolated from spleen, lung, MdLN and ILN of C57BL/6 mice immunized from one to 
four times at 5 day intervals by the intranasal route were analyzed for IFNγ producing cells 
in response to in vitro stimulation with Ova-specific CD8 T cell epitope peptide by the Elispot 
assay as described in the methods section. Average values and errors bars were calculated 
from one experiment using three mice in each group and shown as IFNγ spot forming 
colonies (SFC) for 2x105 plated cells after adjusting for background values from cells 
cultured in medium alone. Responses were considered positive when they were above 10 
SFC/well and double the number obtained in cells cultured with medium alone. The p-values 
were calculated comparing with the medium alone control and values ≤0.05 (*) were 
considered significant. 
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Figure 23. Induction of Ova peptide-specific IFNγ-producing cells by four consecutive 
intranasal immunizations with the Ova +/- α-GalCer as adjuvant. 
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CHAPTER 5: TUMOR CHALLENGE MODEL 
5.1 Induction of HPV Peptide-Specific Adaptive Immunity 
 
We tested whether multiple rounds of intranasal immunization delivering α-GalCer to 
induce repeated activation of NKT cells and sustained adaptive immune responses to co-
administered antigens will also translate into protective efficacy in a tumor challenge model 
in mice. As antigens for this study, we chose two T cell epitope peptides from the E6 and E7 
oncoproteins of the high-risk human papillomavirus type 16, the virus associated with a 
variety of orogenital neoplasia including cervical cancer and oropharyngeal lesions. These 
HPV-16 E6 and E7 peptide sequences were identified in earlier published studies from our 
laboratory to be associated with HPV-specific memory immunity in patients with recurrence-
free survival post-ablative treatment for HPV-induced cervical intraepithelial neoplasia, and 
thus were recognized to serve as potential therapeutic vaccine candidates. Previously, 
these peptides (Q15L from the E6 region and Q19D from the E7 region) were shown to 
induce adaptive CD4+ and CD8+ T cells immune responses when delivered to mice in two 
doses by the intranasal route using admixed cholera toxin (CT) adjuvant.(4) We adopted this 
model for the current experiments by including an additional group of mice that received α-
GalCer adjuvant along with the HPV-16 E6/E7 peptides. Mice were immunized twice at five 
day intervals by the intranasal route with either the HPV peptides alone or admixed with α-
GalCer or CT. On day ten after the first immunization (five days after the second 
immunization), mice were sacrificed to measure adaptive immune responses using IFNγ 
Elispot assay to ascertain the effectiveness of α-GalCer adjuvant, relative to CT. Mice 
receiving CT+HPV peptides showed potent adaptive immune response to each peptide in 
the lung, as well as positive responses in the MdLN and spleen with significant levels above 
the medium alone control in the spleen and lung (Figure 24 A). Immunization with α-
GalCer+HPV peptides also resulted in strong immune responses to both of the peptides in 
the lung, spleen, and MdLN at a similar level as observed in mice immunized with CT+HPV 
(Figure 24 B, A).   
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Figure 24. Induction of antigen-specific immune responses by intranasal 
immunization with HPV peptides admixed with either cholera toxin (CT) or α-GalCer 
(aGC) as adjuvant. Groups of C57BL/6 mice were immunized twice at five day intervals by 
the intranasal route with a mixture of Q19D and Q15L peptides corresponding to the E6 and 
E7 oncoproteins of HPV-16, respectively, admixed with either CT adjuvant (A) or aGC 
adjuvant (B). Cells isolated from spleen, lung, and MdLN were analyzed for peptide-specific 
IFNγ-producing cells by the Elispot assay as described in the methods section and shown 
as IFNγ spot forming colonies (SFC) for  2x105 input cells. Average values and standard 
errors were calculated for three mice in each group. Responses were considered positive 
when they were above 10 SFC/well and double the number obtained in cells cultured with 
medium alone. The p-values were calculated by comparing with the medium alone control 
and values ≤0.05 (*) are considered significant. 
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Figure 24. Induction of antigen-specific immune responses by intranasal 
immunization with HPV peptides admixed with either cholera toxin (CT) or α-GalCer 
(aGC) as adjuvant.  
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5.2 Vaccination against HPV Protein-Expressing Tumor using CT Adjuvant 
 
Having confirmed the effectiveness of α-GalCer adjuvant for inducing immune 
responses to the co-administered HPV peptide antigens, we next tested the efficacy of this 
immunization regimen. We first performed tumor challenge experiments in mice using the 
CT adjuvant shown earlier to be effective. Mice were administered the prophylactic 
immunization twice at five days intervals by the intranasal route with a mixture of CT and 
HPV peptides Q15L and Q19D. At ten days after the first dose, mice were challenged 
subcutaneously with TC-1 tumor cells, an EL4 mouse tumor cell line engineered to express 
the E6 and E7 proteins (219). Tumor burden was determined by measuring the surface area 
every two days using vernier calipers. Control mice immunized with the CT adjuvant alone 
were all sacrificed by 14 days post-tumor challenge due to large tumor burden, whereas 
mice receiving CT+HPV peptides showed complete protection against tumor growth (Figure 
25 A). We next tested this model in a therapeutic setting in which mice received the first 
immunization of CT+HPV peptides by the intranasal route at the first sign of tumor growth 
and received subsequent doses at 5-6 day intervals up to three doses. Mice immunized with 
CT+HPV peptides showed a slowing trend in tumor growth starting around 29 days after 
tumor challenge, with significant differences in tumor growth relative to the CT alone control 
group at day 40 post-challenge (Figure 25 B). Regression could not be followed further due 
to large tumor burden in control mice. These results suggest that earlier and perhaps more 
frequent therapeutic immunization may further slow tumor growth in these mice. 
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Figure 25. Intranasal immunization with HPV peptides using cholera toxin (CT) 
adjuvant protects mice against challenge with TC-1 tumor cells. (A) Prophylactic tumor 
challenge study: Two experimental groups of C57BL/6 mice were immunized by the 
intranasal route with the mixture of Q19D and Q15L peptides (corresponding to the E6 and 
E7 oncoproteins of HPV-16, respectively) along with CT adjuvant (CT+HPV Pep) or CT 
alone twice at 5 day intervals, and 1 week after the last immunization injected 
subcutaneously on the right flank with 2x105 TC-1 tumor cells (expressing the HPV-16 E6 
and E7 oncogenes) per mouse. The percentages of tumor-free mice were plotted over a 
period of 30 days. (B) Therapeutic tumor challenge study: Naïve mice were challenged on 
the right flank with 2x105 TC-1 tumor cells per mouse as described above, and one group of 
mice was then immunized thrice (correspondingly with the arrows)  with either the mixture of 
Q19D and Q15L peptides along with CT adjuvant (CT+HPC Pep) or with adjuvant alone (CT 
alone). The size of the tumors (length x width) was measured at several times and 
expressed as surface area (mm2). Mice immunized with CT+HPV peptides exhibited a delay 
in tumor growth which was significant 40 days post-tumor challenge, as determined for the 
individual days by the student t-test with significance at p≤.05(*). 
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Figure 25. Intranasal immunization with HPV peptides using cholera toxin (CT) 
adjuvant protects mice against challenge with TC-1 tumor cells. 
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5.3 Vaccination against HPV Protein-Expressing Tumor using α-GalCer Adjuvant 
 
Based on these encouraging results, we tested the prophylactic and therapeutic 
immunizations using α-GalCer+HPV peptides delivered by the intranasal route. Prophylactic 
immunizations were given twice, five days apart, and mice were tumor challenged ten days 
after the first dose. As with CT, α-GalCer+HPV peptides afforded complete protection 
against syngeneic TC-1 tumor cells expressing E6 and E7 (Figure 26). Mice that were 
treated therapeutically were immunized twice at a six day intervals starting at the first sign of 
tumor growth. Relative to the mice immunized with α-GalCer alone, mice immunized with α-
GalCer+HPV peptides were observed to show significant differences in tumor size by day 11 
post-tumor challenge (Figure 27 A). In this experiment, an additional group of mice was 
immunized with α-GalCer+HPV peptides that were earlier injected with the EL4 tumor cells 
expressing an irrelevant antigen, OVA, known as EG7.Ova. These tumors grew at a 
drastically accelerated rate compared to TC-1 tumors and, therefore, the mice were 
euthanized by day 28, by which time a significant difference in tumor size was observed 
relative to that in immunized mice challenged with the TC-1 tumors (Figure 27 A). 
A repeat experiment was performed comparing protective efficacy of intranasal 
immunization with α-GalCer+HPV peptides to α-GalCer alone, but eliminating challenge with 
the unrelated EG7.Ova tumor and including control groups of mice mock immunized with 
PBS or immunized with the HPV peptides alone without inclusion of α-GalCer adjuvant. 
Immunizations were delivered 14 days apart. Mice immunized with α-GalCer+HPV peptides 
showed a decreased tumor growth rate compared to PBS alone control, but the differences 
did not reach significance (Figure 27 B). Of note, the mice immunized twice with α-GalCer 
alone experienced accelerated tumor growth as compared to PBS control (Figure 27 B). 
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Figure 26. Prophylactic intranasal immunization with HPV peptides using α-GalCer 
adjuvant protects against HPV tumor growth. Prophylactic tumor challenge study: Four 
experimental groups of C57BL/6 mice were immunized by the intranasal route with the 
mixture of Q19D and Q15L peptides (corresponding to the E6 and E7 oncoproteins of HPV-
16, respectively) along with α-GalCer adjuvant (aGC+HPV) or α-GalCer alone twice at 5 day 
intervals, and 1 week after the last immunization injected subcutaneously on the right flank 
with 2x105 TC-1 tumor cells (expressing the HPV-16 E6 and E7 oncogenes) or 3x106 
EG7.Ova cells (control) per mouse. The percentages of tumor-free mice were plotted over a 
period of 40 days. 
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Figure 26. Prophylactic intranasal immunization with HPV peptides using α-GalCer 
adjuvant protects against HPV tumor growth.  
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Figure 27. Therapeutic intranasal immunization with HPV peptides using α-GalCer 
adjuvant delays HPV tumor growth. (A) Naïve mice were challenged on the right flank 
with 2x105 TC-1 cells (expressing E6 and E7 oncogenes of HPV-16) or EG7.Ova (HPV-
negative) tumor cells per mouse. Mice were then immunized by the intranasal route twice 
correspondingly with the depicted arrows with either α-GalCer adjuvant alone or along with 
the mixture of Q19D and Q15L peptides (corresponding to the E6 and E7 oncoproteins of 
HPV-16, respectively). The size of the tumors (length x width) was measured o as surface 
area (mm2). Mice immunized with aGC+HPV peptides exhibited a delay in TC-1 tumor 
growth as compared to mice immunized with α-GalCer alone which was significant between 
11 and 28 days post-tumor challenge. Mice injected with EG7.Ova tumor cells and 
immunized with aGC+HPV peptides showed no control of the tumor growth. (B) Naïve mice 
were challenged on the right flank with 2x105 TC-1 tumor cells and immunized twice by the 
intranasal route at 11 and 25 days post-challenge with PBS, α-GalCer alone, HPV peptides 
alone or mixture of α-GalCer and HPV peptides. Intranasal immunization with aGC+HPV 
peptides slowed TC-1 tumor growth compared to mock immunization with PBS or HPV 
peptides alone, but immunization with α-GalCer adjuvant alone resulted in acceleration of 
tumor growth. The difference in tumor size was which significant between mice immunized 
with α-GalCer alone and those immunized with aGC+HPV peptides at 23 and 25 days post-
tumor challenge, as measured by the student t-test with significance at p≤.05(*). 
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Figure 27. Therapeutic intranasal immunization with HPV peptides using α-GalCer 
adjuvant delays HPV tumor growth. 
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CHAPTER 6: DISCUSSION 
 
The purpose of this study was to investigate the hypothesis that the route utilized to 
administer α-GalCer adjuvant leads to differential responses by NKT cells, i.e. activation 
versus anergy, as measured by IFNγ production. We also hypothesized that the IFNγ-
producing capacity of NKT cells in response to α-GalCer directly influences induction of 
adaptive immune responses to co-administered antigens. We tested this by combining 
intravenous and intranasal routes for sequential immunizations with ovalbumin +/- α-GalCer, 
and subsequently measuring activation of NKT cells and DC, and induction of antigen-
specific T cell activity. Based on past and present studies from our group and those reported 
in the literature, we surmised the liver and lung to be the primary responding tissues after 
intravenous and intranasal immunization, respectively, for scoring immune responses 
specific to α-GalCer and antigen administrations.  
A single intravenous immunization activated NKT cells to produce IFNγ in all tissues 
tested. However, this activated NKT phenotype did not translate to positive adaptive 
responses in any tissue but the spleen. The first dose was followed by either an IV or IN 
secondary dose. As expected, the second IV dose resulted in NKT cell anergy in the liver, 
which is the responding tissue to IV immunization, accompanied by a lack of DC activation 
indicating that the anergy induced by the first IV immunization could not be overcome by 
immunization via the mucosal intranasal route in this tissue. This was corroborated by a lack 
of adaptive immune response in the liver. In the lung, however, the trend was different. In 
mice that received the IV-IV regimen of immunization, the initial dose strongly activated NKT 
cells, but subsequent to the second dose there was a lack of IFNγ production combined with 
expression of other “anergy” markers (e.g. PD-1). However, NKT cells from mice that 
followed the IV-IN regimen were able to produce large amounts of IFNγ in response to the 
second dose of α-GalCer, indicating reactivation of NKT cells. Thus, in the lung, it appears 
that mucosal immunization is able to overcome the anergy induced by the initial systemic 
immunization (as evident by results from the IV-IV mice), and this is not the case in the 
systemic-responding liver tissue. The spleen and MdLN followed a similar trend as the liver, 
where NKT cells were not reactivated after the second IN dose. However, strong adaptive 
immune responses occurred in both tissues after IV-IN immunization, suggesting that IFNγ 
production by the activated NKT cells may not be the only mechanism of adjuvant effect 
induced by α-GalCer administration. This experiment, however, shows that mucosal 
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intranasal immunization is able to overcome NKT cell anergy induced by initial systemic 
immunization, at least in the lung tissue, the main responding tissue to intranasal 
immunization.  
When the immunization scheme began with an intranasal dose, NKT cells from all 
tissues tested were strongly activated to produce IFNγ. A second intranasal dose 
reactivated NKT cells in the responding lung tissue, but not in the liver. In addition, lung DCs 
were strongly activated as was adaptive immunity. When the second dose was administered 
intravenously, NKT cells were reactivated in the liver (responding tissue to this route of 
immunization) suggesting a lack of anergy development subsequent to the initial intranasal 
α-GalCer delivery. However, after the IN-IV regimen, NKT cells were not reactivated in the 
lung. The results of the IN-IV and IN-IN immunizations strongly indicate that NKT cell 
activation is a tissue specific response that may also depend on the route of immunization. 
The third intranasal dose was administered in order to see the expected anergy phenotype 
after IN-IV immunization as well as to determine if IN-IN immunization induces anergy. In the 
lung, a third IN dose did not activate NKT cells to produce IFNγ, either after IN-IV or IN-IN 
immunization. This contrasts the trend seen in the lung after IV-IN immunization, where 
mucosal delivery overcame the anergy induced by systemic immunization. Perhaps by 
including the additional primary IN dose, which very strongly activated the NKT cells, the 
capacity to be reactivated to the same degree was diminished. It stands to reason that 
despite the strength of IV immunization, immunizing via a route that targets a particular 
tissue will activate the cells more strongly than immunizing via a route that targets tissues 
other than that of interest. This strong activation may present roadblocks to further 
activation, not dissimilar to anergy induction after IV immunization in the liver. In fact, the 
study of four consecutive intranasal immunizations indicates that anergy may in fact be 
induced by multiple intranasal immunizations, but that this happens over the course of 
several immunizations rather than one. Interestingly, the IN-IN-IN scheme maintained the 
ability to activate DCs despite lack of IFNγ production, but the IN-IV-IN scheme did not. A 
third IN dose was not able to reactivate either IN-IV or IN-IN mouse NKT cells in the liver, 
indicating again that IN immunization is not able to overcome anergy in systemic-responding 
tissues as well as the fact that route of immunization plays a role in the ability to activate 
target NKT cells in particular tissues. Once again, other tissues tested revealed mixed 
results. Adaptive immunity induction did not correspond in that in many instances where 
NKT cells were not activated, adaptive immune responses remained positive or even 
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improved on the first IN dose (which induced strong NKT cell activation). This observation 
points to the idea that adaptive immune induction does not depend solely on IFNγ 
production by the NKT cells, and that the adjuvanticity provided by α-GalCer may follow a 
more complex mechanism of action for downstream events. 
This evidence raises several questions about the nature of NKT cell IFNγ production 
and its role in enhancing adaptive immune responses. Our previous studies point to the 
necessity of α-GalCer for inducing these adaptive immune responses (221). In fact, IFNγ 
production in general has been shown to be indispensable for induction of adaptive 
immunity (222). Furthermore, it is known that NKT cell activation influences events beyond 
trans-activation of DCs such as activation of NK cells, which have been implicated as the 
active cells responsible for the anti-tumor activity of α-GalCer (222). And despite acquiring 
an anergic phenotype, NKT cells maintain their ability to produce IL-4 in response to α-
GalCer (175), pointing to the fact that anergy in these cells affects certain cell processes 
more than others. Therefore, it is unclear whether IFNγ production by NKT cells in response 
to activation by α-GalCer leads directly to adaptive immune responses or perhaps other 
cytokines produced by these cells, even in their anergic state, could be responsible for 
trans-activating DCs and/or influencing the induction of adaptive immune responses to co-
administered antigens. It is also possible that the network of communication between 
different immune cell subsets that is responsible for induction of adaptive immunity is more 
complicated and involves additional factors beyond NKT cells and DCs.  
From observations of these data, I believe there are two factors that may determine 
how the route of α-GalCer administration and subsequent IFNγ production by NKT cells 
influence the induction of NKT cell anergy. First, NKT cells must reach a certain threshold of 
activation to become anergic. This may explain why systemic immunization, which is more 
potent than mucosal immunization at activating NKT cells to produce high levels of IFNγ, 
induces anergy after a single dose while it takes multiple mucosal immunizations to do so. 
The second factor may be that the route of immunization targets the adjuvant effect to 
certain tissues, thus allowing more potent activation of NKT cells in the targeted tissues than 
would occur at the same site using a different route. Thus, the level of NKT cell activation, 
as measured by IFNγ production, is dependent on both the route of α-GalCer administration 
(to target the tissue of interest) and a threshold of activation. These factors together could 
dictate the proficiency with which subsequent doses of α-GalCer reactivate NKT cells. For 
example, a single IV immunization will not activate NKT cells in the lung as proficiently as an 
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IN dose. This may explain why immunization following an IV-IN scheme results in strong 
reactivation  of NKT cells after the second dose; reactivation is likely afforded both by the 
initial activation not reaching its peak, and by the second immunization targeting the 
response to the desired tissue. When the second dose (following IV) was delivered by the IV 
route, NKT cells produced IFNγ to a lesser degree than after a second IN dose because 
lung NKT cells were not targeted, but to a measurable degree because the first IV dose did 
not activate NKT cells to the same threshold as would an initial IN dose. Differential tissue-
dependent responses may be due to several factors including harnessing different APCs to 
present α-GalCer or changes in microenvironment of the tissue.  
Interestingly, these studies suggested that a stronger IFNγ response by NKT cells 
activated by α-GalCer does not necessarily translate to better adaptive immunity. In multiple 
instances, undetectable IFNγ levels corresponded to strong adaptive immune response. As 
we have previously shown that α-GalCer is indispensable for inducing these adaptive 
immune responses after each dose (221), these observations indicate that perhaps the 
strength of NKT IFNγ production resulting from the initial dose of α-GalCer is more important 
than in subsequent doses, where perhaps other cell types have been primed to play a more 
significant role in enhancing adaptive responses than the NKT cells themselves. These 
other cell types may require NKT cell activation but not necessarily repeated IFNγ 
production by NKT cells in order to be activated themselves, allowing downstream events to 
enhance adaptive immunity.  
I have also obtained data supporting the idea that multiple intranasal doses (up to 
three) of α-GalCer may induce NKT cell anergy. In NKT cells which have become anergic 
due to systemic immunization, the cells are polarized to Th2 responses, which are believed 
to play a suppressive role in cytotoxic immunity (223, 224). For example, after initial 
exposure to α-GalCer, subsequent exposure leads to decreased NKT cell IFNg and 
decreased activation of NK cells to produce IFNg (157). NK cells have been implicated as 
the primary cell type responsible for the anti-tumor effects of α-GalCer (222). If this is also 
true after the delivery of multiple doses of α-GalCer by the mucosal route, it could offer a 
possible explanation as to why, in the therapeutic tumor study, multiple doses of α-GalCer 
alone delivered by the intranasal route resulted in progression of subcutaneous tumor 
growth; the NKT cells may have become anergic and polarized to Th2 phenotype which 
would promote tumor growth rather than suppress it. Dosing with α-GalCer+antigen 
controlled tumor growth, indicating that perhaps antigen is necessary early on to prime and 
100 
 
activate downstream immunity which can compensate for the effect of NKT cell anergy if it is 
being induced after multiple doses of intranasal α-GalCer. Future studies will be important to 
determine if this differential effect will be seen in repeat experiments as well as to determine 
the mechanism behind it and the downstream immune players mediating the immune 
response.  
We have yet to discover if there is a point at which IFNγ is no longer produced after 
intranasal administration and how this complete lack of production may affect adaptive 
immunity. In our study employing four intranasal doses of α-GalCer, the data points to the 
possibility that the level of activation of adaptive immunity is tissue dependent, and that it is 
possible that multiple doses of intranasal α-GalCer will eventually lead to a state in which 
adaptive immunity is no longer activated. This, however, is in contrast to the trend seen in 
the lung after three IN doses. What we are able to induce is that if NKT cells are playing a 
less significant role in induction of adaptive immunity after each dose (as suggested by the 
combined route studies), perhaps there is a point at which their activation becomes 
unnecessary and other immune cells are able to take over. Thus, more studies are 
necessary to determine the role of repeated vaccination with α-GalCer+antigen in both 
induction of NKT cell anergy and in inducing adaptive responses. Activation of NKT cells 
must be better characterized by measuring other cytokines and when they are produced. 
The role of other immune players, including APCs and NK cells, must also be studied. 
Additionally, efforts should be made to better characterize the mechanism by which 
activated NKT cells may directly induce adaptive immunity in various tissues. A difference in 
NKT cell biology, APC receptor expression, and even tissue microenvironment may be 
playing a role in inducing differential responses in a tissue dependent manner. Perhaps 
these differences can account for the varying degrees of NKT cell anergy in multiple tissues 
in response to the same immunization scheme. If this is the case, this information can be 
used to target NKT cells to more strongly activate them as well as to avoid anergy, both 
important factors in moving α-GalCer adjuvant studies out of mouse models and into primate 
models and human clinical trials.  
 
 
  
101 
 
CHAPTER 7: SUMMARY AND CONCLUSIONS 
 
This study identified that varying the route of α-GalCer administration results in 
differential NKT cell activation and induction of anergy which is tissue-dependent. In this 
study, we showed that a single IV dose of α-GalCer+Ova activated NKT cells to produce 
IFNγ in the systemic-responding liver tissue and induced adaptive immune responses. In 
agreement with published studies (193), we found that a second systemic immunization with 
α-GalCer resulted in NKT cell anergy in the liver in terms of IFNγ production. Delivery of the 
second dose by the mucosal intranasal route was unable to overcome anergy in the liver. In 
contrast, while a second IV dose revealed the lung NKT cells to be anergic as well, a 
second IN dose overcame the anergy in this mucosal-responding tissue to induce IFNγ 
production by NKT cells and positive adaptive immune responses which were greatly 
elevated above a single IV dose. The liver lacked significant adaptive responses to 
secondary immunization. The induction of anergy, or lack thereof, following these two 
immunization regimens (IV-IV vs. IV-IN) reveals this tissue-dependence of NKT cells which 
varies by the route utilized. 
Furthermore, in the comparison of IN-IN-IN immunization to IN-IV-IN immunization, 
we found a similar trend indicating a tissue-dependence of the NKT cell response based on 
immunization route. Two intranasal doses activated NKT cells in the mucosal-responding 
lung tissue, but not in the systemic-responding liver. When the second dose was delivered 
systemically, the NKT cells in the liver were reactivated but not in the lung. In order to 
determine the presence or absence of anergy, we delivered a third intranasal dose and 
found that NKT cells were not reactivated in the lung or the liver following IN-IV-IN or IN-IN-
IN immunization. This examination provided further evidence of the tissue-dependent 
activation of NKT cells based on route of immunization. Furthermore, this study indicated 
both that multiple intranasal doses can induce NKT cell anergy, which we confirmed in our 
regimen utilizing four IN doses, and also that the degree to which NKT cells are activated 
plays a role in whether or not anergy is induced. Those cells that are activated to a lesser 
degree after a dose of α-GalCer are less susceptible to anergy than cells that are more 
highly activated, allowing them to be reactivated by a second dose of α-GalCer.  
While the mechanism of NKT cell anergy is not yet well understood, it is clear that 
NKT cells play a vital role in the effectiveness of α-GalCer as an adjuvant, as lack of 
inclusion in our mucosal vaccination strategy resulted in a lack of adaptive response (221). 
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In these studies, we found time and again evidence that the activation status of NKT cells in 
terms of IFNγ production did not directly correlate to induction of adaptive immune 
responses. The mechanism for activation of adaptive responses in this system is not yet well 
defined. If the mechanisms of α-GalCer-mediated induction of adaptive immunity can be 
elucidated, α-GalCer will show further potential as an effective adjuvant for vaccines against 
infectious diseases or cancer. We reported earlier that repeated immunization by the 
intranasal or oral route using α-GalCer as an adjuvant induced systemic and mucosal 
immune responses to co-administered antigens that improved with each subsequent 
administration (221). These data are consistent with reports from other groups showing 
protection against viral infections and tumor challenge with intranasal vaccination employing 
α-GalCer adjuvant (225, 226). The studies presented here suggest that while intranasal 
immunization does not completely circumvent the induction of NKT cell anergy, the 
differential NKT cell activation based on responding tissue suggests that immunization route 
can be an important tool to circumvent anergy in order to allow for multiple doses of α-
GalCer and thus improved immune responses that may extend beyond adaptive immunity. 
This is highly significant because clinical utility of α-GalCer could be fully realized by 
identifying and harnessing these differential responses to α-GalCer immunization in order to 
optimize α-GalCer adjuvant activity and to avoid its suppressive effects. Future experiments 
should be aimed at providing the mechanistic understanding of the benefits of mucosal 
immunization to capitalize on the ability of α-GalCer to induce cytotoxic immunity and to 
allow vaccinations to better target the NKT cells to the desired responses.  
Finally, our tumor challenge model utilizing HPV peptides with α-GalCer adjuvant 
delivered by the intranasal route revealed an interesting phenomenon. While immunization 
with α-GalCer+Ova was able to control tumor growth to a degree, multiple doses of α-
GalCer alone by the intranasal route resulted in acceleration of tumor growth. This could be 
due to multiple factors. If NKT cells are in fact being anergized by multiple intranasal doses 
of α-GalCer, perhaps the lack of Th1 responses is lending itself to enhancing suppressive 
effects, including responses by NK cells and IL-13 production by type II NKT cells (155).  
Overall, this study has revealed that NKT cell activation shows tissue dependence 
when mice are immunized by systemic versus mucosal means. The reason for anergy 
induction after systemic immunization has been attributed to the preferential presentation of 
α-GalCer by B cells rather than DCs, which we suspect to be the main APCs active after 
mucosal immunization. This tissue dependence may be harnessed in order to overcome 
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anergy induced in some tissue by targeting presentation of α-GalCer to different APCs. In 
addition, these studies strongly suggest that IFNγ production by NKT cells is not the only 
factor involved in inducing adaptive immune responses with mucosal α-GalCer 
immunization. Even without IFNγ expression, cells were able to produce significant adaptive 
immune responses. Thus, other cytokines made by the NKT cells may play a role in α-
GalCer-mediated adaptive immunity. This investigation suggests that, while α-GalCer has 
proven to be a potent adjuvant in vaccine and anti-tumor formulations, the mechanism of its 
action must be further studied to fully harness its potential.  
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CHAPTER 8: FUTURE DIRECTIONS 
 
These studies sought to determine the consequence of NKT cell activation and 
reactivation on the quality and quantity of adaptive immune responses to co-administered 
antigen, as well as the practical significance of activation of NKT cells in inducing protection 
in a tumor challenge model resulting from mucosal delivery of α-GalCer adjuvant with 
antigen. We initially hypothesized that IFNγ production by NKT cells was responsible for 
induction of strong and improving adaptive immune responses. However, our studies have 
revealed that in the absence of IFNγ production by NKT cells, we are still able to induce, 
and even see improvement in, adaptive immune responses in several tissues tested. When 
anergy of NKT cells is induced by IV immunization, certain tissues, specifically the lung, are 
still able to respond weakly to additional IV immunization and strongly to IN immunization. 
This may be due to differential homing tendencies of α-GalCer-loaded APCs after 
immunization by these routes, or perhaps production of cytokines other than IFNγ by 
anergic NKT cells may be capable of activating antigen presenting cells which then directly 
activate other cell types such as T cells and NK cells, renewing the adaptive responses 
initiated by activated NKT cells. 
 
8.1 THE ROLE OF NKT CELL IFNγ IN INDUCING ADAPTIVE IMMUNITY 
 
Our findings have brought to light several unknowns in regards to the mechanism by 
which α-GalCer acts as an adjuvant to induce adaptive immune responses. The first and 
most obvious question highlighted by these studies is that the role of NKT cell IFNγ 
production in the adjuvant effect of α-GalCer is unclear, and further efforts should be made 
to determine the importance of IFNγ production by NKT cells in inducing adaptive immune 
responses. While the importance of IFNγ has been highlighted in studies using IFNγ 
knockout mice (222), this has the effect of wiping out activity by other cell types functioning 
through this cytokine that could be playing a role in the development of immune response. 
To test the effect of lack of IFNγ production by the NKT cells alone, these cells can be 
isolated from IFNγ knockout mice and adoptively transferred into Ja18 knockout mice, which 
lack NKT cells. After adoptive transfer, mice will be immunized by the intranasal or 
intravenous routes, NKT cells will be identified and analyzed by flow cytometry, and Elispot 
and CTL assays can be used to measure activation of adaptive immunity.  
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8.2 IDENTIFICATION, LOCATION, AND ROLE OF APCS IN α-GALCER PRESENTATION 
 
It is also important to characterize the cell type primarily responsible for α-GalCer 
presentation in each tissue following the various immunization routes. To do this, we can 
isolate the three major cell types with the potential to present α-GalCer, the DCs, 
macrophages, and B cells, by magnetic microbead and FACS isolation methods after 
delivering α-GalCer or mock immunization to the mice by the intravenous or intranasal 
routes. Then, by co-culturing in vitro with the NKT cell hybridoma DN32.D3 and estimating 
IL-2 production as reported earlier (124), we can determine which cell type is picking up and 
presenting the α-GalCer in each tissue (218). Previous work in our lab has led us to believe 
that DCs primarily present α-GalCer after intranasal immunization (218). The Batf3-/- strain 
of mice, which are deficient in migratory subsets of CD8α+ DC (227), hold some interest in 
that they can be used to elucidate whether migration of DCs is necessary to induce the 
responses in any of the tissues studied, particularly in the MdLN. Add something about 
different DC subtypes. 
Along these lines, we must investigate the potential contributions of the resident 
versus migratory subsets of the three major cells types capable of α-GalCer presentation 
(i.e. B cells, DC, and macrophages) to better understand the mechanism of α-GalCer  
presentation and the influence of these presenting populations on the breadth and strength 
of adaptive immunity. We can do this by first measuring the activation time course of α-
GalCer presenting cells by isolating immune cells from various tissues after α-GalCer 
administration, and then analyzing by flow cytometry (228) the specific cell surface markers 
such as CD11b on B cells, the maturation markers MHC class II, CD80, and CD86 on both 
CD8α+ and CD11c+ DC, and CD169 on macrophages along with chemokine receptors used 
for homing such as CXCR5, CCR6, and CCR7.  These cells can then be tested to measure 
their capacity to activate the NKT cell hybridoma DN32.D3 in vitro as reported earlier (124). 
Studies have revealed that expression of cell surface markers and even location within the 
GALT changes the ability of DCs to present antigen and activate lymphocytes or promote a 
tolerogenic environment (8, 229-231). 
It is in our interest to determine not only the primary APCs active in presenting α-
GalCer after immunization via various routes, but also the specific sites of α-GalCer 
presentation and how they are affected by route of immunization, whether they are at the 
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local tissues after intranasal and intravenous administration and/or at distant sites after 
transportation by presenting cells. There are multiple strategies to be employed in 
answering this question. One option is to deliver fluorescently labeled α-GalCer by 
intranasal or intravenous routes, and sacrifice mice at various time points between 
immunization and 24 hours. By staining the various antigen presenting cell types and NKT 
cells using immunohistochemistry techniques, we can determine the location of α-GalCer 
presentation. A second option is to identify DCs, macrophages, and B cells, after delivering 
fluorescently-labeled α-GalCer, by sacrificing immunized mice at multiple time points and 
staining single-cell suspensions with fluorescently-labeled antibodies to analyze the location 
of α-GalCer and the cells on which it is presented using flow cytometry. 
In addition to studying the migration patterns of the potential antigen-presenting cells, 
it is possible that NKT cells themselves may be migrating to distant tissues to induce 
adaptive responses distally, an idea that is supported by the data presented in this study, 
e.g. MdLN. An important aspect of the adjuvant potential of NKT cells relates to their 
capacity to activate DC for efficient induction of antigen-specific T and B cell responses. 
Therefore, we should also perform functional analysis of the NKT cells, similar to analysis of 
APCs, to determine the role of chemokines and chemokine receptors (e.g. CXCL16/CXCR6, 
CCL22/CCR4, CXCL9/CXCR3) influencing migration (232-234) by flow cytometry, 
immunohistochemistry, and qPCR of RNA isolated from different tissues. Additionally, we 
can compare the preferential migration of NKT cells using an adoptive transfer model by 
isolating the NKT cells from CD45.1 B6 mice after intranasal immunization with α-GalCer 
and adoptively transferring to CD45.2 B6. After 24 hours, we can stain for and view 
congenic NKT cells using flow cytometry to enumerate cells in each tissue and determine if 
activated NKT cells preferentially migrate to the spleen or the lung compared to un-
stimulated NKT cells. In addition, we must simultaneously measure activation markers of the 
DCs as well as any APCs we determine are playing a presenting role from the previous 
future study to correlate with the effect of stimulated NKT cells. 
 
8.3 IDENTIFICATION OF NKT CELL MARKERS OF ANERGY AND ACTIVATION 
 
Finally, it has long been in our interest to determine the differences in gene 
expression between anergic NKT cells and activated NKT cells. For example, PD-1 
expression has been shown to play a role in induction of anergy, as blockage of the PD-
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1/PD-L1 interaction avoids induction of anergy after systemic immunization (199, 235). It is 
possible, then, that other phenotypic and functional markers play a role both in induction of 
anergy and selective re-activation of NKT cells after mucosal immunization. For instance, 
inhibitory receptors such as Qa-1b ligand NKG2A and CTLA-4 have been previously studies 
(236, 237). Global microarray analysis identifies differentially expressed genes, in our case 
in NKT cells activated by mucosal versus systemic α-GalCer delivery.  It is possible that 
certain pathways/mechanisms involved in classical T cell anergy could also be involved in 
NKT anergy, including the blockade of the MAP-kinase pathway, upregulation of Egr-2 via 
the NF-AT pathway (238), and impaired NF-kB pathway signaling (239). We will collect cells 
from liver tissues of mice at different time points (2, 6, 24 and 72h) after intravenous or 
intranasal α-GalCer delivery using the Pan T cell isolation kit II (from Miltenyi Biotech) 
followed by flow sorting to purify NKT cells on the basis of the Aqua-,CD3+,CD8-,NK1.1+ 
phenotype.  Since the T cell receptor on activated NKT cells is down regulated soon after α-
GalCer presentation, tetramer staining may not identify the NKT cells and therefore, we can 
additionally use the natural killer cell receptor CD160 to guide isolation of pure populations 
of NKT cells. The RNA must be isolated and quality confirmed. Then total RNA must be 
amplified and biotin-labeled through an Eberwine procedure and hybridized to Illumina WG6 
mouse whole-genome arrays. It has been suggested that gene set enrichment analysis 
(GSEA) (240) is beneficial to match our results with previously identified gene sets from 
mSigDB, such as those for exhausted CD8 T cells (241). Subsequently, selected genes 
differentially expressed in the two NKT cell populations of interest can be validated by real-
time qPCR analyses. This microarray analysis would provide both information about NKT 
cell gene expression as well as possible receptors or ligands that may be interacting with 
different APCs and how they modulate induction of NKT cell anergy.  
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8.4 IDENTIFYING DIFFERENTIAL ROLES OF α-GALCER IN CANCER TREATMENT 
 
Our tumor experiments in this study have uncovered an interesting phenomenon in 
which intranasal immunization with α-GalCer alone has the effect of accelerating tumor 
growth. Previous studies have shown that a single intravenous immunization with α-GalCer 
in fact controls tumor growth, but multiple IV immunizations result in acceleration (189). Our 
observations could be due to the fact that multiple intranasal immunizations with α-GalCer 
alone are in fact anergizing NKT cells, as is the case with multiple IV immunizations, and 
thus NKT cells become skewed toward Th2 responses, namely production of IL-13 which 
represses cytotoxic activities and promotes tumor growth (155). However, when α-GalCer is 
co-administered with antigen, tumor growth rate was reduced as compared to growth after 
mock immunization with PBS. In this case, we believe our previous studies support the idea 
that the addition of antigen to the α-GalCer vaccine promotes Th1 responses and a cytotoxic 
environment that controls the tumor growth. Further studies need to be conducted to identify 
the cytokine and cell players active in our model. First, studies should be done on the effect 
of multiple intranasal immunizations with α-GalCer alone as have been done with α-
GalCer+antigen to determine if there is a differential effect of NKT cells in the presence or 
absence of antigen. Flow cytometry methods and ELISA can be used to identify differences 
in cytokine production and NK activation between α-GalCer and α-GalCer+antigen treated 
mice; for example IFNγ and IL-4 profiles should be compared to levels of other Th2 
cytokines such as IL-13 and IL-21, which has been shown to both stimulate CD8+ T cells 
and NK cells while inhibiting activation of DCs (242, 243). In addition, it is important to 
investigate the role of regularly recurring immunizations versus a set number of doses in 
controlling tumor growth. Perhaps consistent immunizations, meaning administered for 
longer duration or at a shorter intervals, will better control and perhaps even reduce tumor 
burden in these mice. Finally, it is important that we be able to test this vaccine in a more 
biologically relevant manner. A vaginal challenge with HPV E6 and E7 expressing virus 
appropriate for mouse use is necessary to validate the findings that this vaccine is effective 
at controlling the effects of HPV infection. This is important as this can show that 
immunization with this vaccine is not only applicable in treating cervical neoplasia but can 
also serve as a therapeutic treatment for patients that do not have cancer but are infected 
with the virus.   
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